Introduction {#s1}
============

Systemic Lupus Erythematosus (SLE) is characterized by progressive dysregulation of the innate and adaptive arms of the immune system, which ultimately leads to loss of immune tolerance in B and T lymphocytes and the production of autoantibodies (Abs) by Ab-secreting B cells (ASCs) ([@bib64]). The hallmark SLE autoAbs recognize nuclear proteins and nucleic acids ([@bib18]), which are also ligands for TLR7 and TLR9 that are expressed by innate immune cells and B cells ([@bib3]). SLE autoAbs bound to their autoAgs form immune complexes, which are responsible for many of the clinical manifestations of SLE, particularly those associated with organ damage ([@bib18]). Consistent with the important role for B cells and ASCs in SLE pathogenesis ([@bib51]), the only new drug approved to treat SLE in decades, Belimumab, targets B cells.

Inflammatory cytokines and chemokines also contribute to SLE pathogenesis ([@bib2]). SLE patient PBMCs often exhibit a type I interferon (IFN) transcriptional signature and systemic IFNα is elevated in many patients ([@bib41]). It is less well appreciated that IFNγ is also increased in some SLE patients ([@bib11]; [@bib19]; [@bib43]) and that a distinct IFNγ transcription signature can be detected in PBMCs from a portion of SLE patients ([@bib9]; [@bib67]). Interestingly, elevated serum IFNγ can be observed years before IFNα or autoAbs are detected in SLE patients and much earlier than clinical disease ([@bib37]; [@bib36]). Consistent with these observations, B cells from SLE patients can exhibit signs of prior IFNγ exposure. For example, two IFNγ-inducible proteins, CXCR3 and T-bet, are more highly expressed by circulating B cells from SLE patients compared to healthy controls ([@bib19]; [@bib40]; [@bib34]; [@bib65]; [@bib24]). Moreover, data from mouse SLE models show that clinical disease is dependent on B cell-specific expression of the IFNγR and the IFNγ- induced transcription factors (TF) STAT1 ([@bib13]; [@bib22]; [@bib63]) and T-bet in some ([@bib49]; [@bib35]) but not all ([@bib22]; [@bib14]) models. Taken together, these data suggest that IFNγ-driven inflammation may contribute to SLE B cell-driven pathophysiology.

Two interrelated populations of circulating B cells present in SLE patients, namely the CD11c^hi^ B cells, which are also called age associated B cells (ABCs) ([@bib26]; [@bib48]), and the IgD^neg^CD27^neg ^B double negative (B~DN~) B cells, which are often referred to as 'atypical' memory B cells ([@bib66]; [@bib44]), are reported to express the IFNγ-inducible TF T-bet. These B cells, which may have been exposed to IFNγ at some step in their developmental process, are present in low numbers in the blood or tonsils of healthy individuals ([@bib15]) and are reported to be expanded in chronically infected, aging and autoimmune individuals (reviewed in [@bib39]), including patients with SLE ([@bib65]; [@bib24]). The CD11c^hi^ population found in SLE patients is heterogeneous and contains CD11c-expressing IgD^neg^CD27^+^ switched memory (B~SW~) cells, IgD^neg^CD27^neg^ naïve (B~N~) cells and B~DN~ cells ([@bib65]). The B~DN~ population is also heterogeneous and can be subdivided using CD11c and CXCR5 into the DN2 (CD11c^hi^CXCR5^neg^) subset, which express T-bet, and the DN1 (CD11c^lo^CXCR5^+^) subset, which does not express T-bet ([@bib24]).

Despite extensive data showing that these overlapping populations of CD11c^hi^ B cells and B~DN~ cells are expanded in a number of human diseases ([@bib39]), our understanding regarding their origin and function is incomplete. Although initial studies examining B~DN~ cells from malaria or HIV-infected individuals described these B cells as anergic (reviewed in [@bib44]), more recent studies reported that the CD11c-expressing IgD^neg^CD27^+^CD21^lo^ activated B~SW~ cells from influenza vaccinated humans ([@bib30]) and HIV infected patients ([@bib27]), as well as the CD11c^hi^ cells from SLE patients ([@bib65]) and the CD11c^hi^ DN2 cells from SLE patients ([@bib24]) possess phenotypic and molecular characteristics of pre-ASCs. Both the CD11c^hi^ B cells and the more narrowly defined DN2 subset from SLE patients differentiate into ASCs following stimulation ([@bib65]; [@bib24]). Moreover, the T-bet^hi^ DN2 subset from SLE patients can produce autoAbs ([@bib24]), suggesting that these cells can potentially contribute to disease.

Since T-bet^hi^ DN2 pre-ASCs produce autoAbs and correlate with disease severity in SLE patients ([@bib24]), we set out to identify the signals that control the development and differentiation of this population into ASCs. Here we show that expansion of the DN2 cells in SLE patients correlates with systemic concentrations of IFNγ and IFNγ-induced cytokines. We demonstrate that activation of naïve B (B~N~) cells from healthy donors or SLE patients with IFNγ-producing T cells or IFNγ+TLR7/8 and BCR ligands induces formation of a T-bet^hi^ pre-ASC population that is phenotypically, transcriptionally and functionally similar to the SLE T-bet^hi^ DN2 subset. We show that IFNγ signals significantly augment ASC differentiation by sensitizing B~N~ cells to respond to BCR, IL-2 and TLR7/8 signals and by promoting global epigenetic changes in the activated B cells that lead to significantly increased chromatin accessibility surrounding binding sites for the key ASC commitment TFs, BLIMP1 and IRF4. We find IFNγ-dependent differentially accessible regions (DARs) within the *IL21R* and *PRDM1* (BLIMP1) loci and show that early IFNγ signaling promotes increased IL-21R expression and responsiveness. Finally, we observe that the key IFNγ-regulated epigenetic changes in the *in vitro* generated T-bet^hi^ B~DN~ pre-ASC subset and the molecular signals required to induce ASC development are conserved in the SLE patient DN2 cells. Collectively, these data suggest that IFNγ signals can augment ASC development and may regulate the formation of pathogenic autoreactive pre-ASCs in some SLE patients.

Results {#s2}
=======

Expansion of T-bet^hi^ DN2 cells correlates with systemic IFNγ levels in SLE patients {#s2-1}
-------------------------------------------------------------------------------------

Recent studies from our group ([@bib59]) revealed that differentiation of mouse B cells activated in the presence of IFNγ-producing T cells was dependent on B cell intrinsic expression of the IFNγR and the IFNγ-induced transcription factor (TF), T-bet. This result fit well with data from our group ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and others ([@bib49]; [@bib35]) showing that B cell intrinsic expression of T-bet is required for the development of autoAb-mediated disease in SLE mouse models and suggested that IFNγ signaling in B cells might also regulate development of ASCs from autoreactive B cells. Consistent with this possibility, we and others ([@bib65]; [@bib24]) identified a population of circulating T-bet-expressing B cells in SLE patients, referred to as DN2 cells ([@bib24]), that express high levels of T-bet and exhibit phenotypic and functional properties of pre-ASCs. Based on these data, we postulated that the T-bet^hi^ DN2 pre-ASC population that is expanded in a subset of SLE patients likely arises in response to IFNγ-dependent signals. To test this hypothesis, we first assessed whether expansion of the T-bet^hi^ DN2 pre-ASC subset in SLE patients correlated with IFNγ levels in these patients. Consistent with our prior studies using a different cohort of SLE patients ([@bib24]), we observed that a subset of our SLE patients presented with an expanded population of circulating IgD^neg^CD27^neg^ (double negative, B~DN~ cells) ([Figure 1a--b](#fig1){ref-type="fig"}) that could be subdivided into CD11c^+^CXCR5^neg^ DN2 cells and CD11c^neg^CXCR5^+^ DN1 cells ([Figure 1c](#fig1){ref-type="fig"}). The DN2 cells, but not the DN1 cells, uniformly expressed high levels of T-bet ([Figure 1d](#fig1){ref-type="fig"}) and also expressed high levels of CD19 and FcRL5 ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}). In agreement with our prior studies, the T-bet^hi^ B~DN~ cells (gated as in [Figure 1---figure supplement 2b](#fig1s2){ref-type="fig"}) expressed intermediate levels of the ASC-promoting TFs, Blimp1 and IRF4 ([Figure 1e--f](#fig1){ref-type="fig"},) and their presence correlated with anti-Smith autoAb titers in the patients ([Figure 1g](#fig1){ref-type="fig"}). Next, we measured cytokines in plasma from the SLE patients ([Figure 1h-k](#fig1){ref-type="fig"}). Consistent with our hypothesis, we observed a significant positive correlation between IFNγ, as well as the IFNγ-induced cytokines CXCL10, IL-6 and TNFα, and the frequency of T-bet^hi^ DN2 cells in these individuals ([Figure 1h](#fig1){ref-type="fig"}). These data therefore indicated that the circulating T-bet^hi^ B~DN~ cells present in our SLE patient cohort were phenotypically identical to the previously described ([@bib24]) DN2 pre-ASC subset and that this pre-ASC population is most expanded in SLE patients with elevated amounts of autoAbs, IFNγ and IFNγ-driven inflammatory cytokines.

![Expansion of the T-bet^hi^ DN2 subset in SLE patients correlates with systemic inflammatory cytokine levels.\
(**a--f**) Characterization of T-bet^hi^ B cells in peripheral blood B cell subsets from healthy donor (HD) and SLE patients. Gating strategy to identify CD38^hi^CD27^+^ ASCs, B cells (non-ASCs) (a, left) and double negative IgD^neg^CD27^neg^ (B~DN~) cells (**a, right**) from the peripheral blood of HD and SLE patients. Frequency of B~DN~ cells (**b**) within the total B cells. Subdivision of the SLE B~DN~ population into CXCR5^+^CD11c^lo^ DN1 and T-bet^hi^ CXCR5^neg^CD11c^hi^ DN2 populations (**c**) with T-bet expression levels (**d**) in each subset shown as a histogram. Expression of BLIMP1 (**e**) and IRF4 (**f**) by ASCs, T-bet^hi^ B~DN~ cells and T-bet^lo^ B cells from SLE patients. Representative flow plots and mean fluorescence intensity (MFI) expression of BLIMP1 and IRF4 in each population are shown. (**g**) Correlation analysis between frequency of circulating T-bet^hi^ B~DN~ cells and anti-Smith autoAb titers in SLE patients. (**h--k**) Correlation (**h**) between plasma cytokine levels and frequency of T-bet^hi^ B~DN~ cells in SLE patient peripheral blood. Plasma concentration of IFNγ (**i**), CXCL10 (**j**) and TNFα (**k**) in HD (blue symbols) and SLE patients (red symbols). See [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} for analysis of T-bet expressing B cells in the Yaa.*Fcgr2b*^-/-^ SLE mouse model. See [Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"} for additional phenotypic characterization of T-bet^hi^ B cells in SLE patients. See [Figure 1---figure supplement 2b](#fig1s2){ref-type="fig"} for gating strategy to identify T-bet^hi^ B~DN~ cells (DN2 cells) in SLE patients. Individual human subjects in each analysis are represented by a symbol. Horizontal black lines represent the median (**b,i--k**) within the group. Data shown from n = 20 HD and 40 SLE patients (**b**), representative flow plots from 16 SLE patients (**c--d**), 3 SLE patients (**e--f**), 16--18 SLE patients (**g--h**) or 5 HD and 26 SLE patients (**i--k**). Statistical analyses were performed using a non-parametric Mann-Whitney test (**b,i--k**), a one-way paired T test (**e--f**) or Spearman Correlation test (**g--h**). Correlation *P* and r values listed in the figure. *P* values \*≤0.05, \*\*\<0.01, \*\*\*\<0.001.](elife-41641-fig1){#fig1}

IFNγ-producing Th1 cells promote development of T-bet^hi^ B~DN~ cells and ASCs {#s2-2}
------------------------------------------------------------------------------

Since IFNγ can induce T-bet expression in B cells ([@bib59]) and the T-bet^hi^ DN2 pre-ASCs are expanded in SLE patients with higher systemic levels of IFNγ, we predicted that the IFNγ might regulate the formation of T-bet^hi^ pre-ASCs. To test this, we developed an *in vitro* B cell/T cell mixed lymphocyte reaction (MLR) paired co-culture system ([Figure 2a](#fig2){ref-type="fig"}) containing B~N~ cells (purified as described in [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}) purified from the peripheral blood or tonsil of one HD and highly polarized human Th1 and Th2 effectors ([@bib69]), which were generated *in vitro* using purified naïve peripheral blood T cells isolated from a second unrelated HD. The Th1 cells expressed T-bet and produced IFNγ and IL-8 following restimulation while Th2 cells expressed GATA-3 and produced elevated levels of IL-4, IL-5, and IL-13 ([Figure 2---figure supplement 1b--c](#fig2s1){ref-type="fig"}). Since neither the Th1 nor Th2 cells produced IL-21 following restimulation ([Figure 2---figure supplement 1d](#fig2s1){ref-type="fig"}), we added IL-21 to the co-cultures to ensure optimal B~N~ activation ([@bib17]; [@bib61]) and included IL-2 to enhance the survival of the T effectors ([@bib46]). After 6 days in culture, approximately 50% of the HD B cells activated in the presence of IFNγ-producing Th1 cells (Be1 cells) expressed T-bet while very few (\<3%) of the HD B cells activated with IL-4 producing Th2 cells (Be2 cells) upregulated T-bet ([Figure 2b](#fig2){ref-type="fig"}). Approximately half of the T-bet^hi^ B cells present in the Be1 cultures downregulated IgD and these cells were CD19^hi^CD27^neg^CD11c^+^FcRL5^+^CD23^neg^ ([Figure 2c](#fig2){ref-type="fig"}). Therefore, activation of B~N~ cells with Th1 cells and IL-21 +IL-2 resulted in the formation of a T-bet^hi^ IgD^neg^CD27^neg^ B~DN~ population that was phenotypically similar to the SLE patient-derived T-bet^hi^ DN2 cells.

![ASC development from B~N~ precursors is enhanced in Th1 containing co-cultures.\
Cartoon (**a**) depicting day 6 paired co-cultures containing Th1 (Be1 co-cultures) or Th2 (Be2 co-cultures) effectors generated from the same HD, B~N~ cells from a second allogeneic HD and exogenous IL-21 and IL-2. Flow cytometric analysis showing T-bet expression (**b**) on gated HD B cells (non-ASCs) from Be1 and Be2 co-cultures. Phenotyping (**c**) of day 6 B cell-gated Be1 cells showing T-bet expression in combination with other surface markers. (**d--g**) ASC development in HD day 6 paired Be1 and Be2 co-cultures showing representative flow plots (**d**) and frequencies (**e**) of CD38^hi^CD27^+^ ASCs in CD19^+/lo^-gated B lineage cells. Frequencies of IgM^+^ (**f**) or IgG^+^ (**g**) ASCs in day 6 paired Be1 and Be2 co-cultures. See [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for B~N~ isolation strategy and characterization of polarized Th1 and Th2 effectors. See [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} for gating strategy to identify IgG^+^ and IgM^+^ ASCs. See [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} for proliferation analysis of B cells in paired day 6 HD Be1 and Be2 co-cultures. Analyses in (**b--c**) are from representative co-cultures (n \> 30). Experiments (**e--g**) performed on 15 (**e**), 8 (**f**) or 6 (**g**) independent paired Be1 and Be2 co-cultures. Statistical analyses were performed using a non-parametric Wilcoxon paired t test (**e**) or paired Student's t test (**f--g**). *P* values \*\<0.05, \*\*\<0.01, \*\*\*\*\<0.0001.](elife-41641-fig2){#fig2}

In addition to observing the T-bet^hi^ B~DN~ pre-ASC like population in the Be1 co-cultures, we also identified CD38^hi^CD27^+^ ASCs in both the Be1 and Be2 co-cultures ([Figure 2d](#fig2){ref-type="fig"}). However, we always found more ASCs in the Be1 co-cultures, even across multiple experiments using B~N~ and T effectors from different HD pairs ([Figure 2e](#fig2){ref-type="fig"}). To address whether the increased ASC formation observed in the Be1 co-cultures was limited to isotype switched or unswitched B cells, we measured the frequency of IgM and IgG-producing (gated as in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) ASCs across multiple paired Be1 and Be2 co-cultures. Again, we found that ASCs, regardless of isotype, were greatly enriched in the Be1 co-cultures ([Figure 2f--g](#fig2){ref-type="fig"}). This increase in ASCs in the Be1 co-cultures was not due to intrinsic differences in the proliferative rates of the cells in each culture but rather that a higher proportion of the Be1 cells at each cell division committed to the ASC lineage ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). These data indicated that Be1 co-cultures efficiently promoted the formation of T-bet^hi^ B~DN~ pre-ASC-like cells and ASCs.

T-bet^hi^ B~DN~ cells induced with Th1 cells and IL-21 are pre-ASCs {#s2-3}
-------------------------------------------------------------------

Given the phenotypic similarities between the *in vitro* generated T-bet^hi^ B~DN~ cells and SLE patient T-bet^hi^ DN2 cells and the fact that the *in vitro* cultures containing T-bet^hi^ B~DN~ cells also efficiently formed ASCs, we predicted that the *in vitro* generated Tbet^hi^ B~DN~ cells were likely to be pre-ASCs. To test this, we first asked whether the *in vitro* generated T-bet^hi^ B~DN~ cells were transcriptionally related to SLE patient-derived T-bet^hi^ DN2 pre-ASCs or to ASCs from HD. We therefore sort-purified IgD^neg^CD27^neg^ B~DN~ cells ([Figure 3a](#fig3){ref-type="fig"}) from 3 independent paired day 6 Be1 and Be2 co-cultures and performed RNA-seq analysis ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). We identified 427 differentially expressed genes (DEGs) between the B~DN~ cells from the Be1 and Be2 co-cultures ([Figure 3b](#fig3){ref-type="fig"}). Consistent with our data showing that T-bet was selectively upregulated in the B cells from Be1 co-cultures, we observed significantly higher levels of *TBX21* mRNA in the *in vitro* induced B~DN~ Be1 cells compared to B~DN~ Be2 cells ([Figure 3c](#fig3){ref-type="fig"}). Next, we used Gene Set Enrichment Analysis (GSEA) to compare the transcriptomes of the *in vitro* generated Be1 and Be2 B~DN~ cells to the T-bet^hi^ DN2 population isolated from SLE patients ([@bib24], [Supplementary file 2](#supp2){ref-type="supplementary-material"}) and to curated ASC transcriptome datasets ([@bib1]; [@bib62]). Consistent with our phenotyping data, the transcriptome of the T-bet expressing B~DN~ Be1 cell subset was highly enriched relative to the B~DN~ Be2 cells for genes that are specifically upregulated in the SLE-derived T-bet^hi^ DN2 subset ([Figure 3d](#fig3){ref-type="fig"}). Moreover, the transcriptome of the *in vitro*-induced B~DN~ Be1 population was significantly enriched in expression of genes that are upregulated in ASCs compared to B~N~ cells ([Figure 3e](#fig3){ref-type="fig"}), mature B cells ([Figure 3f](#fig3){ref-type="fig"}) and switched memory B cells ([Figure 3g](#fig3){ref-type="fig"}). In addition, genes that are direct targets of IRF4 and upregulated in ASCs ([@bib56]) were significantly enriched in the *in vitro* generated T-bet^hi^ Be1 B~DN~ cells relative to the Be2 B~DN~ cells ([Figure 3h](#fig3){ref-type="fig"}). Consistent with this finding, we observed that the Be1 T-bet^hi^ B~DN~ cells had undergone multiple rounds of cell division ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) and expressed intermediate levels of IRF4 ([Figure 3i--j](#fig3){ref-type="fig"}), when compared to the CD38^hi^CD27^+^ ASCs and the IgD^+^CD27^neg^ B cells present in the Be1 cultures.

![Th1-induced T-bet^hi^ B~DN~ cells are pre-ASCs.\
(**a--h**) Transcriptome analysis of *in vitro* generated IgD^neg^CD27^neg^ B~DN~ cells from Be1 and Be2 co-cultures. RNA-seq analysis performed on IgD^neg^CD27^neg^ B~DN~ cells (gating in panel **a**) that were sort-purified from day 6 HD Be1 and Be2 co-cultures. Heat map (**b**), showing 427 differentially expressed genes (DEGs) based on FDR \< 0.05. T-bet mRNA expression levels (**c**) in B~DN~ cells from day 6 Be1 and Be2 co-cultures. Gene Set Enrichment Analysis (GSEA, panels **d-h**) comparing transcriptome profile of *in vitro* generated B~DN~ cells from Be1 and Be2 co-cultures with published DEGs identified in different B cell subsets. Data are reported as Enrichment Score (ES) plotted against the ranked B~DN~ Be1 and Be2 gene list (n = 11598). DEG lists used for GSEA include: DEGs that are upregulated in sort-purified SLE patient-derived T-bet^hi^ DN2 cells (CD19^hi^IgD^neg^CD27^neg^CXCR5^neg^IgG^+^) compared to other SLE patient-derived mature B cell subsets (**d**, [@bib24]); DEGs that are upregulated in human plasma cells (ASCs) relative to: B~N~ cells (**e**, [@bib1]), total B cells (**f**, [@bib62]) or switched memory (B~SW~) B cells (**g**, [@bib1]); and IRF4-dependent upregulated target genes in ASCs (**h**, [@bib56]). (**i--j**) IgD^neg^CD27^neg^ T-bet^hi^ B~DN~ cells express intermediate levels of IRF4. Gating strategy (**i**) to identify CD38^hi^CD27^+^ ASCs, IgD^+^CD27^neg^ B cells and IgD^neg^CD27^neg^ B~DN~ cells in day 6 Be1 co-cultures generated from HD B~N~ cells. Expression of T-bet and IRF4 (**j**) by ASCs (blue), IgD^+^CD27^neg^ B cells (green) and IgD^neg^CD27^neg^ B~DN~ cells (red) from day 6 Be1 co-cultures. (**k--l**) B~DN~ Be1 cells rapidly differentiate into ASCs. B~DN~ cells from day 6 HD Be1 and Be2 cultures were sort-purified, Cell-Trace Violet (CTV) labeled and incubated 18 hr in conditioned medium. Enumeration of ASCs (CD19^lo^CD38^hi^CD27^+^) in the undivided cells (D0, ) and the cells that divided one time (D1, ). Representative flow plots (**k**) showing the frequency of cells in D0 or D1 in each culture and the frequency of CD19^lo^CD38^hi^CD27^+^ ASCs present in the D0 or D1 fraction. Panel (**l**) reports frequency of ASCs within the cultures from 3 independent experiments. See [Supplementary file 1](#supp1){ref-type="supplementary-material"} for B~DN~ Be1 and Be2 RNA-seq data set and [Supplementary file 2](#supp2){ref-type="supplementary-material"} for SLE patient-derived T-bet^hi^ B~DN~ DEG list. See [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} for proliferation profile of the T-bet^hi^IRF4^int^ B~DN~ subset in Be1 cells. RNA-seq performed with 3 samples/subset derived from 3 independent paired co-culture experiments. Statistical analysis performed with unpaired (**c**) or paired (**l**) Students t test. Nominal *P* values (**d--h**) for GSEA are shown. *P* values \*\<0.05, \*\*\<0.01.](elife-41641-fig3){#fig3}

To determine whether the Be1 T-bet^hi^ B~DN~ cells were functional pre-ASCs, we sort-purified the IgD^neg^CD27^neg^ B~DN~ cells from day 6 Be1 and Be2 co-cultures, labeled the sorted B~DN~ cells with Cell Trace Violet (CTV), incubated the cells for 18 hr in conditioned media and enumerated CD38^hi^CD27^+^ ASCs in the cultures. As expected, the sorted Be1 and Be2 B~DN~ cells were activated, with 47--65% of the cells undergoing one cell division within 18 hr ([Figure 3k](#fig3){ref-type="fig"}). CD38^hi^CD27^+^ ASCs were only detected in proliferating cells ([Figure 3k](#fig3){ref-type="fig"}), indicating that the sorted B~DN~ cells include pre-ASCs that are poised to differentiate within one round of replication. Although ASCs were detected in the cultures containing either Be1 or Be2 B~DN~ cells, significantly more ASCs were found in cultures containing the sorted T-bet expressing Be1 B~DN~ cells ([Figure 3l](#fig3){ref-type="fig"}). Thus, activation of B~N~ cells with Th1 cells and IL-21 +IL-2 gave rise to a population of T-bet^hi^ B~DN~ cells that were phenotypically, transcriptionally and functionally similar to the T-bet^hi^ DN2 pre-ASCs that are expanded in SLE patients ([@bib24]).

IFNγ is required for *in vitro* development of T-bet^hi^ B~DN~ pre-ASCs and ASCs from B~N~ cells {#s2-4}
------------------------------------------------------------------------------------------------

Since the *in vitro* generated Th1-induced T-bet^hi^ B~DN~ subset and the SLE patient derived T-bet^hi^ DN2 pre-ASC population ([@bib24]) were quite similar, we asked whether we could use our *in vitro* co-culture system to define the minimal signals required to generate this potentially pathogenic population of T-bet^hi^ pre-ASCs. Using Ingenuity Pathway Analysis (IPA) to interrogate the Be1 and Be2 B~DN~ cell RNA-seq data-sets, we identified predicted upstream regulators of the T-bet^hi^ B~DN~ pre-ASC transcriptional network. These included antigen receptor signaling molecules, like Btk, cytokines, like IFNα, IFNγ, IL-2 and IL-21, and cytokine-induced TFs, like STAT1 and STAT3 ([Figure 4a](#fig4){ref-type="fig"}). In addition, both TLR7 and TLR9 were predicted as upstream regulators of the T-bet^hi^ B~DN~ Be1 cells ([Figure 4a](#fig4){ref-type="fig"}). This was unexpected, given that we did not add exogenous TLR ligands to the co-cultures, however, endogenous TLR7 and TLR9 ligands are known to be released by dying cells *in vitro* ([@bib57]).

![IFNγ is required for development of T-bet^hi^ B~DN~ cells and regulates ASC formation and recovery.\
(**a**) Ingenuity Pathway Analysis (IPA) to identify predicted upstream direct and indirect regulators of the HD B~DN~ Be1 transcriptome. IPA performed using the 427 DEG (B~DN~ Be1 over B~DN~ Be2; FDR \< 0.05) identified in the RNA-seq analysis described in [Figure 3b](#fig3){ref-type="fig"}. The predicted activation state (z-score of B~DN~ Be1 over B~DN~ Be2) of each regulator/signaling pathway is shown as bar color (orange, activated; blue, inhibited) with predicted upstream regulators sorted in order of significance (overlap *P* value). Regulators with an overlap *P*-value\<0.00001 are shown. (**b--d**) IPA-identified stimuli induce development of T-bet^hi^IRF4^int^ B~DN~ pre-ASC-like cells from HD B~N~ cells. Cartoon (**b**) depicting in vitro stimulation conditions to activate purified HD B~N~ cells with cytokines (IL-2, BAFF, IL-21, IFNγ), anti-Ig and R848 for 6 days. Phenotypic characterization of day 6 activated cells showing expression of IRF4 and T-bet (**c**) and other markers (**d**) on the IgD^neg^CD27^neg^ B~DN~ subset. (**e--h**) Cartoon (**e**) depicting HD B~N~ cells activated with anti-Ig +cytokine cocktail (IFNγ, IL-2, IL-21, BAFF) and R848 (ALL) or activated with individual stimuli (as indicated) removed from the cultures. Representative flow plots showing T-bet and IRF4 expression (**f--g**) by day 3 B cells in each culture. Enumeration of CD38^hi^CD27^+^ ASCs (**h**) in day 6 'ALL' cultures. (**i--j**) Transient BCR activation is required for ASC development. Cartoon (**i**) depicting activation of HD B~N~ cells for 3 days with R848, cytokines (IFNγ, IL-2, IL-21, BAFF) ±anti-Ig (Step 1). Cells were then washed and recultured for an additional 3 days with the same stimuli ± anti-Ig (Step 2). Enumeration of CD38^hi^CD27^+^ ASCs (**j**) on day 6 in cultures that were not exposed to anti-Ig during Steps 1 and 2 (-,-); were exposed to anti-Ig throughout Steps 1 and 2 (+,+); were exposed to anti-Ig only in Step 1 (+,-); or were exposed to anti-Ig only in Step 2 (-,+). (**k--l**) IFNγ, R848 and IL-21 are required for ASC development. Cartoon (**k**) showing HD B~N~ cells activated with anti-Ig + cytokine cocktail (IFNγ, IL-2, IL-21, BAFF) and R848 for 3 days (Step 1) and then cultured for an additional 3 days (Step 2) with cytokine cocktail and R848. Alternatively, individual stimuli (as indicated) were excluded from the cultures for all 6 days. Enumeration of day 6 CD38^hi^CD27^+^ ASCs (**l**). See [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"} for % ASCs and number of total cells recovered in cultures lacking individual stimuli. RNA-seq IPA analysis was performed on n = 3 samples/subset derived from 3 independent paired co-culture experiments. Data in (**c--l**) are representative of ≥3 experiments. The recovery of ASCs in (**j, l**) are shown as the mean ±SD of cultures containing purified B~N~ cells from 3 independent healthy donors. Statistical analyses (**j, l**) were performed using one-way ANOVA with Tukey's multiple comparison test. *P* values \*\<0.05, \*\*\<0.01.](elife-41641-fig4){#fig4}

Next, we addressed whether stimulation of B~N~ cells with the IPA-predicted activators of the T-bet^hi^ B~DN~ transcriptional network was sufficient to induce the formation of the T-bet^hi^ B~DN~ pre-ASC population. We therefore stimulated HD B~N~ cells with anti-Ig, cytokines (IFNγ, IL-2, IL-21 and BAFF) and the TLR7/8 ligand, R848 ([Figure 4b](#fig4){ref-type="fig"}) and evaluated the B cells on day 6. We found that \>95% of the B~N~ cells activated with these defined stimuli resembled SLE patient T-bet^hi^ DN2 cells ([@bib24]) as the *in vitro* activated cells were IgD^neg^CD27^neg^ T-bet^hi^IRF4^int^, expressed the DN2 markers, CD11c and FcRL5, and were losing expression of CD21 and CXCR5 ([Figure 4c--d](#fig4){ref-type="fig"}). To address which signals were critical for the *in vitro* development of T-bet^hi^ B~DN~ cells we set up 'all minus one cultures' by activating B~N~ cells for 3 days with or without individual stimuli ([Figure 4e](#fig4){ref-type="fig"}). As expected, when HD B~N~ cells were activated for 3 days in the presence of anti-Ig and all cytokines + R848 (ALL condition), essentially all of the cells upregulated T-bet and IRF4 ([Figure 4f--g](#fig4){ref-type="fig"}). Similar results were observed when the B~N~ cells were activated for 3 days without anti-Ig ([Figure 4f](#fig4){ref-type="fig"}) or without R848, IL-21, BAFF or IL-2 ([Figure 4g](#fig4){ref-type="fig"}). By contrast, when the cells were activated without IFNγ, more than 80% of the cells were T-bet^neg/lo^ ([Figure 4g](#fig4){ref-type="fig"}). While this wasn't particularly surprising, given that T-bet is IFNγ-inducible ([@bib59]), the cells also failed to upregulate IRF4 ([Figure 4g](#fig4){ref-type="fig"}), indicating that IFNγ signals are obligate for the *in vitro* generation of the T-bet^hi^IRF4^int^ B~DN~ pre-ASC like population.

Although HD B~N~ cells activated with anti-Ig, cytokines and R848 developed in an IFNγ-dependent fashion into T-bet^hi^IRF4^int^ B~DN~ pre-ASC like cells ([Figure 4g](#fig4){ref-type="fig"}), CD38^hi^CD27^+^ ASCs did not accumulate in the cultures containing all stimuli ([Figure 4h](#fig4){ref-type="fig"}). This suggested that our defined cultures lacked a factor that was necessary for the differentiation of the T-bet^hi^ pre-ASC-like cells into ASCs. Alternatively, it was possible that one or more of the stimuli present in the cultures either blocked differentiation or needed to be provided transiently during a discrete temporal window. Since anti-Ig was not added in our original *in vitro* Th1 and B~N~ co-cultures, we first examined whether BCR signaling was blocking ASC development. We therefore stimulated B~N~ cells for 6 days with the complete activation cocktail (+,+) or removed the anti-Ig from the activation cocktail for the first three days (-,+), last three days (+,-), or throughout the entire culture period (-,-) ([Figure 4i](#fig4){ref-type="fig"}). Consistent with our prior results, few ASCs were recovered when anti-Ig was included throughout the culture period ([Figure 4j](#fig4){ref-type="fig"}). Similarly, excluding anti-Ig from the culture for all 6 days or for the first 3 days also resulted in poor ASC recovery ([Figure 4j](#fig4){ref-type="fig"}). However, when anti-Ig was present only during the first 3 days of culture ASCs accumulated in the cultures ([Figure 4j](#fig4){ref-type="fig"}). These data therefore argued that early but transient BCR signals were important for the development and recovery of ASCs from cytokine and R848 stimulated B~N~ cells.

Next, we asked whether IFNγ signals were required for the development of ASCs in the culture. We therefore activated B~N~ cells with the cytokine cocktail and R848 for 6 days, including 3 days in the presence of anti-Ig and 3 days without anti-Ig. In individual cultures we excluded specific cytokines or R848 for all 6 days ([Figure 4k](#fig4){ref-type="fig"}). In agreement with our earlier experiment, ASCs were recovered ([Figure 4l](#fig4){ref-type="fig"}) when B cells were transiently activated with anti-Ig in the continuous presence of R848 and the complete cytokine cocktail. Although elimination of BAFF or IL-2 from the cultures decreased the number of ASCs recovered from the cultures ([Figure 4l](#fig4){ref-type="fig"}), neither cytokine was obligate for ASC development. By contrast, and consistent with prior reports showing that ASC development from B~N~ cells requires IL-21 ([@bib17]; [@bib61]), no ASCs were detected in the cultures lacking IL-21 ([Figure 4l](#fig4){ref-type="fig"}). Likewise, ASC recovery in cultures lacking R848 or IFNγ was also at background levels ([Figure 4l](#fig4){ref-type="fig"}). Collectively, the data indicated that formation of the T-bet^hi^IRF4^int^ pre-ASC like population required IFNγ signals while the development and recovery of ASCs were dependent on transient BCR signals, IFNγ, R848 and IL-21.

Temporal control of ASC development from T-bet^hi^IRF4^int^ pre-ASCs by IFNγ, R848 and IL-21 {#s2-5}
--------------------------------------------------------------------------------------------

Although the number of ASCs recovered from cultures lacking IL-21, R848 or IFNγ was equally low ([Figure 4l](#fig4){ref-type="fig"}), the frequencies of ASCs and number of total cells recovered from each culture differed dramatically ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These data suggested that the different stimuli were likely to play distinct roles in the development and recovery of ASCs. Since IFNγ, but not R848 or IL-21, was required for the formation of the pre-ASC population, we postulated that IFNγ signals would be required during the initial activation (Days 0--3, priming phase) while TLR7/8 and IL-21 signals would be more critical later in the culture period (Days 4--6, differentiation phase). To test this hypothesis, we activated CTV-labeled B~N~ cells for 3 days in the presence of anti-Ig and 3 days without anti-Ig -- while adding the various stimuli minus one during the priming phase (+,-), during the differentiation phase (-,+) or throughout (+,+) the culture period ([Figure 5a](#fig5){ref-type="fig"}). We then measured proliferation, cell recovery and the frequency and number of ASCs present in cultures on day 6 (see [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} for representative flow cytometry plots). Eliminating IFNγ from the cultures during the first 3 days prevented formation of the T-bet^hi^IRF4^int^ pre-ASC like population ([Figure 5---figure supplement 1a](#fig5s1){ref-type="fig"}). Moreover, consistent with our prediction, CD38^hi^CD27^+^ ASCs, whether measured as the frequency ([Figure 5b](#fig5){ref-type="fig"}) or number ([Figure 5c](#fig5){ref-type="fig"}) were essentially undetected in cultures lacking IFNγ in the first 3 days. B~N~ cells that did not receive an IFNγ signal during the priming phase proliferated less over the 6 day culture period ([Figure 5d](#fig5){ref-type="fig"}), resulting in minimal cell recovery on day 6 ([Figure 5e](#fig5){ref-type="fig"}). By contrast, adding IFNγ only during the priming phase was sufficient to induce formation of the T-bet^hi^IRF4^int^ pre-ASC population ([Figure 5---figure supplement 1a](#fig5s1){ref-type="fig"}) and to promote proliferation ([Figure 5d](#fig5){ref-type="fig"}) and cell recovery on day 6 ([Figure 5e](#fig5){ref-type="fig"}). Moreover, addition of IFNγ only during the early priming phase resulted in similar frequencies ([Figure 5b](#fig5){ref-type="fig"}) and numbers ([Figure 5c](#fig5){ref-type="fig"}) of ASCs compared to cultures that contained IFNγ throughout the entire culture period. Thus, early IFNγ signals were required to drive the development of the T-bet^hi^ pre-ASC like subset and the formation and recovery of ASCs in the cultures.

![Temporally distinct regulation of T-bet^hi^IRF4^int^ pre-ASC and ASC development by IFNγ, R848 and IL-21.\
Cartoon (**a**) depicting stimulation of CTV-labeled HD B~N~ cells for 3 days with anti-Ig, R848, IL-21 and IFNγ (Step 1). Cells were washed and re-cultured for 3 days with R848, IFNγ, and IL-21 (Step 2, +,+ condition) or individual stimuli were included in Step 1 only (+,- condition) or in Step 2 only (-,+ condition). Cells from day 6 cultures containing IFNγ (**b--e**), R848 (**f--i**) or IL-21 (**j--m**) in Step 1, Step 2 or both steps were analyzed to determine ASC frequencies (**b, f, j**), ASC recovery (**c, g, k**), cell division (**d, h, l**) and total cell recovery (**e, i, m**). Summary of data (**n**) showing that ASC development and recovery from T-bet^hi^IRF4^int^ B~DN~ pre-ASCs requires early IFNγ, R848 and BCR 'priming' signals and late R848 and IL-21 proliferation and differentiation signals. See [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} for representative flow cytometry plots from each culture showing T-bet^hi^IRF4^int^ B~DN~ cells on day 3, CD38^hi^CD27^+^ ASCs on day 6 and CTV dilution on day 6. Data are representative of ≥3 experiments. The percentage of cells in each division, the frequency of ASCs and cell recovery (total and ASCs) are shown as the mean ±SD of cultures containing purified B~N~ cells from 3 independent healthy donors. All statistical analyses were performed using one-way ANOVA with Tukey's multiple comparison test. *P* values \*\<0.05, \*\*\<0.01, \*\*\*\<0.001, \*\*\*\*\<0.0001.](elife-41641-fig5){#fig5}

Next, we analyzed when TLR7/8 signals were necessary for ASC development. When R848 was only added during the first 3 days, ASCs could not be detected in the cultures, whether measured as the frequency ([Figure 5f](#fig5){ref-type="fig"}) or number ([Figure 5g](#fig5){ref-type="fig"}) of ASCs. This was due, at least in part, to the fact that proliferation was severely stunted ([Figure 5h](#fig5){ref-type="fig"}), resulting in greatly reduced cell recovery ([Figure 5i](#fig5){ref-type="fig"}) in the day 6 cultures. When R848 was only added to the cultures between days 3--6, we observed no impact on pre-ASC formation ([Figure 5---figure supplement 1d](#fig5s1){ref-type="fig"}) or the frequency of ASCs in the day 6 cultures ([Figure 5f](#fig5){ref-type="fig"}). However, the number of cells recovered on day 6 was significantly reduced ([Figure 5i](#fig5){ref-type="fig"}), which affected the number of ASCs recovered in the cultures ([Figure 5g](#fig5){ref-type="fig"}). Despite the poor recovery of cells in the cultures that received TLR7/8 stimulation only between days 3--6, proliferation of the cells was not impacted ([Figure 5h](#fig5){ref-type="fig"}). These data therefore indicated that R848 played both early and late roles in the development of ASCs, with early TLR7/8 signals appearing to promote B cell survival and late TLR7/8 signals promoting proliferation.

Finally, we assessed when IL-21 signals were required for ASC development. When IL-21 was only included for the first 3 days of the culture, pre-ASCs formed normally ([Figure 5---figure supplement 1g](#fig5s1){ref-type="fig"}) but ASCs could not be detected whether measured by frequency ([Figure 5j](#fig5){ref-type="fig"}) or number ([Figure 5k](#fig5){ref-type="fig"}) of ASCs recovered. The lack of ASCs in this culture correlated with greatly decreased proliferation ([Figure 5l](#fig5){ref-type="fig"}) and cell recovery ([Figure 5m](#fig5){ref-type="fig"}) on day 6. By contrast, the proliferation ([Figure 5l](#fig5){ref-type="fig"}) and recovery ([Figure 5m](#fig5){ref-type="fig"}) of cells stimulated with IL-21 only during the late phase were not significantly different from cells that were stimulated for all 6 days in the presence of IL-21. Moreover, the frequency ([Figure 5j](#fig5){ref-type="fig"}) and number ([Figure 5k](#fig5){ref-type="fig"}) of ASCs recovered from the cultures that were exposed to IL-21 between days 3--6 only were very similar to cells that were stimulated all 6 days in the presence of IL-21. Therefore, late IL-21 signals were sufficient to drive ASC formation. Thus, while inclusion of IFNγ, TLR7/8 ligand and IL-21 throughout the entire culture period promoted optimal ASC recovery, IFNγ and BCR signals were required during the priming phase, IL-21 was necessary during the later expansion and differentiation phase and R848 was important throughout the culture period ([Figure 5n](#fig5){ref-type="fig"}).

IFNγ synergizes with R848 and IL-2 to promote proliferation, IL-21 responsiveness and ASC recovery {#s2-6}
--------------------------------------------------------------------------------------------------

Our data indicated that IFNγ played a non-redundant and critical role in the formation of the Tbet^hi^IRF4^int^ B~DN~ cells *in vitro*, and was necessary for development and recovery of ASCs, even when IL-21 and R848 were present. These data led us to hypothesize that IFNγ signaling might sensitize B cells to respond to other stimuli, like IL-21, IL-2 and TLR ligands, that promote B cell proliferation and differentiation. To test whether IFNγ signals promoted B cell responsiveness to R848 we activated CTV-labeled HD B~N~ cells with anti-Ig, IL-2 and increasing concentrations of R848 in the presence and absence of IFNγ for 3 days, washed the cells and then re-cultured them for an additional 3 days with IL-21 and the same concentration of R848 that the cells were exposed to during the priming phase. On day 6 we measured cell division and ASC formation. Consistent with our earlier experiments ([Figure 5](#fig5){ref-type="fig"}), the B cells remained largely undivided when R848 was completely excluded from the cultures ([Figure 6a](#fig6){ref-type="fig"}). By contrast, when high dose R848 was included in the cultures, the cells proliferated regardless of whether IFNγ was included in the cultures for the first 3 days ([Figure 6b](#fig6){ref-type="fig"}). However, when we activated B~N~ cells with a 100-fold lower dose of TLR7/8 ligand, proliferation was only seen in the cultures that contained IFNγ ([Figure 6c](#fig6){ref-type="fig"}). Moreover, we observed that the frequency of ASCs in the cultures that were activated with low dose TLR ligand in the presence of IFNγ was approximately 10-fold higher than that observed for the cultures that lacked IFNγ ([Figure 6d](#fig6){ref-type="fig"}). Similar results were seen when we cross-titrated the IFNγ and R848 in the cultures ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Thus, exposure of B~N~ cells to IFNγ during the initial priming phase allowed these cells to differentiate even in the face of sub-optimal stimulation with R848.

![IFNγ cooperates with R848, IL-2 and IL-21 to promote development and recovery of ASCs.\
(**a--d**) IFNγ synergizes with subthreshold amounts of TLR7/8 ligand to induce proliferation and differentiation of B~N~ cells. CTV-labeled HD B~N~ cells were activated for 3 days (Step 1) with anti-Ig, IL-2, and increasing concentrations of R848 (as indicated) in the presence or absence of IFNγ (10 ng/ml). Cells were washed and re-cultured for 3 additional days (Step 2) with IL-21 and the same concentration of R848 that was used in Step 1. B cell division was measured on day 6 in cultures that were activated with IFNγ (green circles) or without IFNγ (orange circles) in the presence of no R848 (0 μg/ml, (**a**), high dose R848 (10 μg/ml, (**b**) or low dose R848 (0.1 μg/ml, (**c**). The frequency of CD38^hi^CD27^+^ ASCs (**d**) on day 6 is shown. (**e--i**) IFNγ cooperates with IL-2 to promote ASC development and recovery. Cartoon (**e**) depicting CTV-labeled HD B~N~ cells activated for 3 days (Step 1) with anti-Ig and R848 alone (Be.0); with anti-Ig +R848+IFNγ (Be.IFNγ); with anti-Ig +R848+IL-2 (Be.IL2); or with anti-Ig +R848+IFNγ+IL-2 (Be.γ2). Cells were then washed and recultured for an additional 3 days (Step 2) with R848 and IL-21. The percentage of cells that have undergone cell division (**f**), the total cell recovery (**g**), the ASC frequencies (**h**) and total ASCs recovered (**i**) from each day 6 culture are shown. (**j--k**) Early IFNγ signals regulate IL-21R signaling. Phospho-STAT3 (pSTAT3) expression levels (reported as Mean Fluorescence Intensity (MFI)) in day 3 HD Be.0, Be.IFNγ, Be.IL2 and Be.γ2 cells under basal conditions (**j**) or following 20 min IL-21 stimulation (**k**). See [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} for measurements of ASC formation in cultures containing cross-titrated IFNγ and R848. See [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} for representative flow cytometry plots from Be.0, Be.IFNγ, Be.IL2 and Be.γ2 cells showing CD38^hi^CD27^+^ ASCs and CTV dilution on day 6. See [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"} for representative flow cytometry plots showing pSTAT3 expression. Data are representative of ≥3 experiments and are shown as the mean ±SD of cultures containing purified B~N~ cells from 2 to 3 independent healthy donors. All statistical analyses were performed using one-way ANOVA with Tukey's multiple comparison test. *P* values \*\<0.05, \*\*\<0.01, \*\*\*\<0.001, \*\*\*\*\<0.0001.](elife-41641-fig6){#fig6}

Next, we asked whether the IFNγ priming signals enhanced the early response of B cells to cytokines. We first assessed cooperation between IFNγ and IL-2 as IL-2, while not obligate for ASC development, did significantly enhance ASC recovery in our *in vitro* cultures ([Figure 4](#fig4){ref-type="fig"}). We activated HD B~N~ cells for 3 days with anti-Ig +R848 (Be.0 conditions), anti-Ig +R848+IL-2 (Be.IL2 conditions), anti-Ig +R848+IFNγ (Be.IFNγ conditions) or with anti-Ig +R848+IL-2+IFNγ (Be.γ2 conditions). We then washed and stimulated the cells for an additional 3 days with R848 +IL-21 ([Figure 6e](#fig6){ref-type="fig"}) and evaluated cell recovery and ASC formation (see [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} for representative flow cytometry plots). As expected, we recovered very few viable cells ([Figure 6f--g](#fig6){ref-type="fig"}) and no ASCs ([Figure 6h--i](#fig6){ref-type="fig"}) from the Be.0 cells on day 6. B cell proliferation ([Figure 6f](#fig6){ref-type="fig"}) and recovery of total cells ([Figure 6g](#fig6){ref-type="fig"}) and ASCs ([Figure 6i](#fig6){ref-type="fig"}) were also very low in the Be.IL2 cultures. Consistent with our earlier experiment ([Figure 5](#fig5){ref-type="fig"}), ASCs were easily detected in the Be.IFNγ cultures ([Figure 6h--i](#fig6){ref-type="fig"}). However, when B cells were exposed to both IL-2 and IFNγ during the early priming phase, the number of ASCs recovered on day 6 ([Figure 6i](#fig6){ref-type="fig"}) was significantly more than seen in the Be.IFNγ or Be.IL2 cultures. This was due to an increase in the number of cells recovered ([Figure 6g](#fig6){ref-type="fig"}) and to an increase in the frequency of ASCs ([Figure 6h](#fig6){ref-type="fig"}) in the cultures. Thus, early IFNγ and IL-2 signals cooperate to induce formation and recovery of ASCs.

Finally, since IL-21 signaling was obligate for ASC differentiation in our *in vitro* cultures, we hypothesized that early IFNγ signals might program the B cells to respond to IL-21. To test this hypothesis, we measured phosphorylation of the IL-21R associated TF, STAT3, before and after IL-21 stimulation in day 3 Be.0, Be.IL2, Be.IFNγ and Be.γ2 cells. Day 3 basal levels of phospho-STAT3 were similar and low in the Be.0, Be.IL2 and Be.IFNγ cells and modestly higher in the Be.γ2 cells ([Figure 6j](#fig6){ref-type="fig"}, see [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"} for flow cytometry plots). However, following a 20 min exposure to IL-21, phospho-STAT3 levels were increased significantly in the B cells that were exposed to IFNγ during the priming phase ([Figure 6k](#fig6){ref-type="fig"}), indicating that early IFNγ stimulation enhanced IL-21R signaling. Collectively, these data show that early IFNγ signals sensitize human B~N~ cells to respond more robustly to stimuli, like TLR7/8 ligands, IL-2 and IL-21, that promote B cell activation, proliferation and differentiation.

Early IFNγ signals cooperate with IL-2 and R848 to initiate ASC epigenetic programming and IL-21R expression {#s2-7}
------------------------------------------------------------------------------------------------------------

Our data showed that early IFNγ signals cooperated with both IL-2 and R848 to promote IL-21 dependent ASC formation and recovery. Given the importance of IFNγ in driving the development of the T-bet^hi^ pre-ASC like population, we hypothesized that IFNγ might induce molecular and epigenetic changes that would initiate early commitment to the ASC lineage and/or regulate IL-21R expression and responsiveness. To test this possibility, we used ATAC-seq analysis ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) to identify differentially accessible regions (DAR) in the genome of Be.0, Be.IL2, Be.IFNγ and Be.γ2 cells on day 3 -- a time in which cell recovery was similar in the cultures ([Figure 7a--b](#fig7){ref-type="fig"}, see [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"} for representative flow plots) and the T-bet^hi^ pre-ASC like population was easily detected in the IFNγ-containing cultures. As expected, distinct sets of DAR were found in all 4 groups of activated B cells ([Figure 7c](#fig7){ref-type="fig"}), however the largest number of chromatin accessible regions was seen in the day 3 Be.γ2 cells ([Figure 7c](#fig7){ref-type="fig"}). Moreover, the chromatin accessibility pattern in the Be.γ2 cells appeared to reflect cooperation or synergy between the IFNγ and IL-2 signals ([Figure 7c](#fig7){ref-type="fig"}). Examination of chromatin accessibility within 100 bp surrounding consensus TF binding motifs revealed significant (see [Supplementary file 4](#supp4){ref-type="supplementary-material"} for statistical analyses) enrichment in accessibility near T-bet binding sites in the B cells that were exposed to IFNγ ([Figure 7d](#fig7){ref-type="fig"}). Similarly, accessibility around STAT5 binding motifs was enriched in IL-2 exposed B cells ([Figure 7e](#fig7){ref-type="fig"}). However, the Be.γ2 cells exhibited the greatest enrichment in chromatin accessibility surrounding both T-bet and STAT5 binding sites ([Figure 7d--e](#fig7){ref-type="fig"}), suggesting that IFNγ and IL-2 cooperate to remodel the epigenome. Consistent with this, binding motifs for NF-κB p65 and REL, TFs activated by anti-Ig and TLR7/8 stimulation ([@bib25]), were most accessible in the Be.γ2 cells compared to all other groups ([Figure 7f--g](#fig7){ref-type="fig"}). Moreover, chromatin accessibility surrounding the HOMER-defined IRF4 and BLIMP1 binding motifs ([@bib20]) was also highly enriched in the Be.γ2 cells ([Figure 7h--i](#fig7){ref-type="fig"}). These data therefore suggested that these key ASC initiating TFs were already exerting epigenetic changes to the genome of the Be.γ2 cells, even before these cells were exposed to IL-21. Consistent with this finding, when we examined the *PRDM1* (BLIMP1) locus, we identified 4 DAR that were each more accessible in the Be.γ2 cells relative to the other cells ([Figure 7j](#fig7){ref-type="fig"}). Although none of these DAR contained a T-bet binding motif, each DAR directly aligned with peaks previously identified in a published T-bet ChIP-seq analysis of GM12878 cells ([@bib16]), suggesting that T-bet could be associated with TF complexes that bind to these regulatory regions. Moreover, 3 of the 4 PRDM1-associated DAR were also seen in T-bet^hi^ DN2 cells purified from SLE patients ([Figure 7j](#fig7){ref-type="fig"}), indicating that these DAR were present in the pre-ASC population found in SLE patients.

![IFNγ signaling promotes chromatin accessibility and poises B cells to undergo IL-21 dependent differentiation.\
(**a--b**) Cell division and total cell recovery in day 3 Be.0, Be.IFNγ, Be.IL2 and Be.γ2 cultures generated with HD B~N~ cells. (**c--k**) Chromatin accessibility analysis using ATAC-seq data from day 3 Be.0, Be.IFNγ, Be.IL2 and Be.γ2 cell. Heatmap (**c**) showing 15,917 differentially accessible regions (DAR) based on FDR \< 0.05. Chromatin accessibility plots and histograms for T-bet (**d**), STAT5 (**e**), NF-κB p65 (**f**), NF-κB REL (**g**), IRF4 (**h**) and BLIMP1 (**i**). Plots report reads per million (rpm) in the 100 bp surrounding the transcription factor binding motifs and histograms show accessibility at the indicated motif and for the indicated surrounding sequence. Genome plots showing chromatin accessibility for the *PRMD1* (**j**) and *IL21R* (**k**) loci. DAR are shown and consensus T-bet, IRF4 and STAT5 binding motifs within DAR are indicated. DAR are aligned with previously reported T-bet binding sites in GM12878 cells (assessed by ChIP, [@bib16]) and with ATAC-seq data derived from B cell subsets purified from SLE patients ([@bib24]). Data reported in rpm. (**l--m**) Early IFNγ signals control IL-21R expression levels. Representative flow plots showing IL-21R expression in day 3 (**l**) and day 6 (**m**) Be.0, Be.IFNγ, Be.IL2 and Be.γ2 cells. See [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"} for representative flow plots showing cell division profile. See [Supplementary file 3](#supp3){ref-type="supplementary-material"} for ATAC-seq data. See [Supplementary file 4](#supp4){ref-type="supplementary-material"} for enrichment of TF binding motifs *P* values. ATAC-seq analysis was performed on 3 independent experimental samples/group over 2 experiments. Flow cytometry plots depicting IL-21R expression are representative of ≥2 experiments. Box plots (**d--i**) show 1^st^ and 3^rd^ quartile range (box) and upper and lower range (whisker) of 2 samples/group.](elife-41641-fig7){#fig7}

Finally, given our data showing that IFNγ and IL-2 potentiated signaling through the IL-21R, we examined the 2 DAR assigned to the *IL21R* locus of the day 3 cells ([Figure 7k](#fig7){ref-type="fig"}). One of the DAR contained two putative T-bet binding motifs and was directly aligned with a T-bet ChIP-seq peak from GM12878 cells ([@bib16]) ([Figure 7k](#fig7){ref-type="fig"}). This DAR was only observed in the cells that were exposed to IFNγ and was most enriched in the Be.γ2 population. Interestingly, we identified the same DAR in the SLE patient T-bet^hi^ DN2 cells ([Figure 7k](#fig7){ref-type="fig"}), which are reported to be highly responsive to IL-21 ([@bib24]). To address whether these early IFNγ-dependent epigenetic changes in the *IL21R* were associated with altered expression of IL-21R, we measured IL-21R expression in the day 3 and day 6 stimulated cells. Although day 3 B cells from Be.IFNγ and Be.γ2 cultures expressed slightly higher levels of IL-21R compared to B cells from Be.0 and Be.IL2 cultures ([Figure 7l](#fig7){ref-type="fig"}), IL-21R expression were comparable between all groups at this timepoint. By day 6 however, IL-21R expression levels were 5.5--6-fold higher in the B cells that were cultured in the presence of IFNγ during the first 3 days ([Figure 7m](#fig7){ref-type="fig"}). Taken together, the data suggested that early IFNγ signals synergize with BCR, TLR and IL-2 signals to induce global changes in chromatin accessibility and promote increased TF binding at T-bet, NF-κB, STAT5, BLIMP1 and IRF4 binding sites as well as chromatin remodeling at the *PRDM1* and *IL21R* loci.

SLE patient T-bet^hi^ DN2 cells differentiate into ASCs without a further requirement for BCR stimulation {#s2-8}
---------------------------------------------------------------------------------------------------------

Previous data from our group ([@bib24]) showed that the T-bet^hi^ DN2 cells from SLE patients were transcriptionally distinct from conventional memory cells and, like B~N~ cells ([@bib61]), require IL-21 signals to differentiate. Since our *in vitro* culture system accurately predicted that the T-bet^hi^ DN2 cell differentiation would be IL-21 dependent, we hypothesized that the *in vitro* culture data could be used to make additional testable predictions about the molecular properties of the T-bet^hi^ DN2 cells found in SLE patients. To evaluate this possibility, we first tested the prediction that IFNγ-dependent ASC formation from the B~N~ cells isolated from SLE patients would require transient BCR stimulation. We therefore purified T-bet^lo^ B~N~ cells (see [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} for purification strategy) from the peripheral blood of SLE patients and stimulated the cells with the complete cytokine cocktail (IFNγ, IL-2, IL-21 and BAFF) plus R848 for 6 days in the continuous presence of anti-Ig (+,+), in the complete absence of anti-Ig (-,-) or in the presence of anti-Ig for the first 3 days (+,-) ([Figure 8a](#fig8){ref-type="fig"}). Consistent with our prediction, SLE patient B~N~ cells did acquire phenotypic characteristics of the T-bet^hi^ DN2 subset following *in vitro* activation with R848, IL-2, IFNγ and IL-21 ([Figure 8b](#fig8){ref-type="fig"}). Moreover, the recovery of ASCs in the cultures started with SLE patient B~N~ cells was highly dependent on transient but early stimulation with anti-Ig as continuous stimulation with anti-Ig or no stimulation with anti-Ig reduced both the frequency and number of ASCs recovered in the cultures ([Figure 8c--d](#fig8){ref-type="fig"}). Thus, these data indicated that transient BCR stimulation was required for ASC development from SLE patient-derived B~N~ cells activated with R848, IFNγ, IL-2 and IL-21.

![SLE patient T-bet^hi^ B~DN~ cells rapidly differentiate in ASCs in the absence of BCR stimulation.\
(**a--d**) ASC generation from SLE B~N~ cells requires early but transient BCR activation. Cartoon (**a**) depicting *in vitro* stimulation conditions to activate sort-purified T-bet^lo^ B~N~ cells from SLE patients. B~N~ cells were stimulated for 3 days with R848, cytokines (IFNγ, IL-2, IL-21, BAFF) ± anti-Ig (Step 1) and then washed and recultured for an additional 3 days with the same stimuli ± anti-Ig (Step 2). Cells were analyzed by flow cytometry on day 6 (**b--d**). Phenotypic characterization (**b**) of IgD^neg^CD27^neg^ B~DN~ cells in cultures containing anti-Ig for all 6 days showing expression of T-bet, CD11c, FcRL5, CD21 and CXCR5 by the T-bet^hi^ B~DN~ subset. The frequency (**c**) and number (**d**) of CD38^hi^CD27^+^ ASCs in cultures lacking anti-Ig (-,-), containing anti-Ig for all 6 days (+,+) or exposed to anti-Ig for the first 3 days only (+,-). (**e**) SLE patient T-bet^hi^ B~DN~ cells rapidly differentiate in ASCs. Purified SLE B cell subsets (T-bet^lo^ B~N~, T-bet^lo^ CD11c^neg^CXCR5^+^ CD27^neg^IgD^neg^ DN1 memory cells, T-bet^lo^ CD27^+^ memory B cells (B~mem~) and T-bet^hi^ CD11c^+^CXCR5^neg^ DN2 cells) were stimulated with cytokines (IFNγ, IL-21, IL-2, BAFF) and R848 for 2.5 days then counted and transferred to anti-IgG ELISPOT plates for 6 hr. The frequency of IgG ASCs derived from each B cell subset is shown. See [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} for gating strategy to purify B cell subsets from SLE patients. Data shown in (**c--d**) are from a single SLE individual and are representative of 2 independent experiments. Data reported in (**e**) are representative of 3 independent experiments using B cells sorted from 3 different SLE donors. Statistical analyses were performed using one-way ANOVA with Tukey's multiple comparison test (**d--e**). *P* values \*\<0.05, \*\*\<0.01, \*\*\*\<0.001, \*\*\*\*\<0.0001.](elife-41641-fig8){#fig8}

Based on these data and our *in vitro* experiments, we made two additional testable predictions. First, we postulated that T-bet^hi^ DN2 cells isolated from SLE patients should differentiate without a requirement for BCR stimulation. Second, we predicted that SLE patient T-bet^hi^ DN2 cells should differentiate more rapidly than B~N~ cells. To test these predictions, we sort-purified (see [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} for purification strategy) SLE patient-derived T-bet^hi^ DN2 cells, T-bet^lo^ B~N~ cells and T-bet^lo^ memory B cells, including the IgD^neg^CD27^neg^ B~DN~ memory (DN1 cells; [@bib24]) and IgD^neg^CD27^+^ memory (conventional B~mem~) subsets. We stimulated the cells for 2.5 days with R848, IFNγ, IL-21 and IL-2 and then enumerated IgG-producing ASCs. As expected, the conventional B~mem~ and DN1 memory cells efficiently formed ASCs in this short timeframe ([Figure 8e](#fig8){ref-type="fig"}), while B~N~ cells failed to differentiate ([Figure 8e](#fig8){ref-type="fig"}). Consistent with our predictions, ASCs were easily identified in the day 2.5 cultures containing T-bet^hi^ DN2 cells ([Figure 8e](#fig8){ref-type="fig"}). Indeed, ASC recovery was at least 50-fold higher in T-bet^hi^ DN2 cell cultures compared to the B~N~ cultures and only 2--3 times less than that seen with the memory B cell populations ([Figure 8e](#fig8){ref-type="fig"}). These data therefore suggested that the expanded population of T-bet^hi^ DN2 cells present in some SLE patients likely represent a population of IFNγ, TLR ligand and antigen programmed primary effectors that can rapidly differentiate in a BCR-signaling independent manner into ASCs following IL-21 exposure. The importance of IFNγ in driving human ASC commitment and differentiation in the context of autoimmune disease is discussed.

Discussion {#s3}
==========

Here we show that IFNγ promotes the *in vitro* formation of a T-bet^hi^IRF4^int^ IgD^neg^CD27^neg^ (B~DN~) population that is similar to the T-bet expressing CD11c^hi^CXCR5^neg^ B~DN~ (referred to as DN2 cells) subset found in SLE patients ([@bib24]) and the CD11c^hi^Age-Associated B cells (ABCs) that accumulate in aged and autoimmune mice and humans ([@bib65]; [@bib48]). Both the *in vitro* generated T-bet^hi^IRF4^int^ B~DN~ cells and SLE patient-derived DN2 cells ([@bib24]) exhibit transcriptional and functional properties of pre-ASCs, suggesting that B cell intrinsic IFNγR signals could regulate human ASC responses. While this hypothesis is supported by mouse experiments showing that IFNγ signals enhance autoAb responses ([@bib13]; [@bib22]; [@bib32]) and recent studies from our group demonstrating a role for B cell expression of the IFNγR and the IFNγ-inducible transcription factor T-bet in ASC development ([@bib59]), the role for IFNγ and STAT1 signaling in human B cell differentiation is less clear. In fact, prior data showing that IFNγ has only very modest effects on activation and differentiation of human B cells ([@bib38]; [@bib58]; [@bib47]) and that patients deficient in the IFN-activated transcription factor STAT1 produce Abs in response to some vaccines ([@bib8]; [@bib7]) argue that IFNγ signaling is not obligate for the formation of human ASCs. Our *in vitro* studies do not contradict this conclusion as we also find that human B cells can differentiate in the absence of IFNγ-induced signals. However, we show that B cell intrinsic IFNγ signals significantly enhance ASC differentiation induced in response to stimulation with anti-Ig, TLR7/8 ligand, IL-2 and IL-21. Indeed, we routinely recover 5- to 10 fold more ASCs in the B~N~ cultures that contain IFNγ or IFNγ-producing T cells compared to cultures that lack IFNγ. Thus, we argue that IFNγ signaling has the potential to augment ASC development in settings, like autoimmunity and viral infection, where IFNγ and TLR ligands are present.

Our data show that IFNγ signals, when delivered in conjunction with IL-2 and BCR +TLR7/8 ligand during the initial activation of B~N~ cells, greatly increase ASC recovery *in vitro*. The co-activation of B~N~ cells with IFNγ and IL-2 +BCR +TLR7/8 ligand results in IFNγ-dependent chromatin remodeling and the formation of the T-bet^hi^IRF4^int^ pre-ASC subset. These early IFNγ signals are required for subsequent proliferation and differentiation following stimulation with IL-21 and TLR7/8 ligand. IFNγ is not, in and of itself, a B cell mitogen and is reported to induce apoptosis of human B cells ([@bib5]; [@bib50]). However, we find that IFNγ synergizes with TLR7/8 ligand to promote multiple rounds of B cell proliferation -- an important prerequisite of human ASC differentiation ([@bib60]). Although *in vitro* experiments using human B cells show that IFNγ can synergize with TLR7 and CD40 signals to promote upregulation of Bcl6 and the acquisition of a germinal center-like phenotype ([@bib22]), our data extend these studies to show that IFNγ and TLR7/8 signals also cooperate to promote human B cell differentiation. These results are analogous to studies showing that IFNα-directed signals can enhance TLR7-mediated human B cell differentiation ([@bib23]; [@bib4]). Given the considerable overlap between genes regulated by IFNα and IFNγ ([@bib43]), it is possible that IFNα and IFNγ may augment TLR7 signaling in human B cells by similar mechanisms.

Our *in vitro* data suggest multiple ways in which early IFNγ priming signals promote subsequent ASC differentiation and recovery. First, we show that IFNγ cooperates with IL-2, BCR, TLR7/8 ligand to globally alter the epigenetic landscape of the activated B cells and to specifically increase chromatin accessibility surrounding NF-κB, STAT5 and T-bet binding sites. While it is not particularly surprising that IFNγ signaling induces increased T-bet expression and alterations in chromatin accessibility around T-bet binding sites (see for example [@bib21]), the finding that chromatin accessibility surrounding NF-κB and STAT5 binding motifs is also regulated by IFNγ suggests that IFNγ must augment TLR7/8 and IL-2-dependent signaling. This is consistent with our *in vitro* data showing synergistic effects on ASC recovery when IFNγ is combined with IL-2 or R848. Second, we show that IFNγ promotes commitment to the ASC lineage by inducing expression of IRF4 and modifying chromatin accessibility surrounding IRF4-binding sites within regulatory regions in the genome of the activated B~N~ cells. Third, we find that IFNγ signals promote chromatin accessibility within the *PRDM1* (BLIMP1) locus and initiate chromatin remodeling around BLIMP1-binding sites within the genome of the activated B~N~ cells. Finally, we demonstrate that IFNγ signals alter chromatin accessibility within the *IL21R* locus of the activated B~N~ cells and that this change in accessibility is associated with IFNγ-dependent, increased expression of the IL-21R by the activated B~N~ cells and with increased responsiveness of these cells to IL-21, as measured by phosphorylation of STAT3. Collectively, these data suggest that IFNγ signals, when combined with BCR, TLR and IL-2R signals, poise human B~N~ cells to differentiate in response to IL-21.

One key finding from this study is that IFNγ-augmented ASC formation and recovery is highly reliant on TLR7/8 activation by its RNA and RNA/protein ligands, which are derived from viral pathogens and dead and dying cells ([@bib3]). Signaling through TLR7 is known to be important in SLE as prior studies reveal that SNPs in the human *TLR7* locus ([@bib33]) and overexpression of TLR7 in mice ([@bib42]) are associated with increased SLE susceptibility while deletion of TLR7 protects mice from the development of SLE ([@bib10]). Our data show that deletion of the IFNγ-inducible transcription factor T-bet in B lineage cells prevents autoAb responses in a mouse model ([@bib42]) of TLR7-dependent SLE. Moreover, our data demonstrates that B cell intrinsic IFNγ signaling induces a TLR7/8 hyperresponsive state in human B cells. This finding does not appear to be due to IFNγ-dependent changes in the expression of TLR7 by the B cells (data not shown). Rather, we find that IFNγ-exposed B~N~ cells can respond and differentiate into ASCs when exposed to 100-fold lower concentration of TLR7/8 ligands than normally used to activate B cells. Given that we observed that even low levels of IFNγ are sufficient to synergize with suboptimal concentrations of TLR7/8 ligands, we predict that B cells from autoimmune patients with detectable systemic levels IFNγ will be highly sensitive to the presence of endogenous and exogenously derived TLR7 ligands.

Our data predict that TLR7-driven ASC responses are likely to be further enhanced in individuals who have increased levels of circulating IFNγ. Consistent with this, we show that SLE patients who have higher systemic levels of IFNγ also have more T-bet^hi^ DN2 cells and higher autoAb titers. We and others ([@bib65]; [@bib24]) also report that the size of the T-bet^hi^ DN2 population correlates with disease activity, particularly in African-American SLE patients. However, it is important to note that T-bet^hi^ DN2 cells are unlikely to represent a purely 'pathogenic' population as we also find an inducible population of vaccine-specific T-bet^hi^ CD27^neg^ DN2 cells in healthy individuals who were immunized with inactivated influenza virus (data not shown). Similarly, others report ([@bib30]; [@bib27]) a T-bet expressing CD27^+^CD21^lo^ switched memory subset with pre-ASC attributes, which is induced following vaccination or infection. Thus, we speculate that the T-bet^hi^ B cells, which are found in HD and autoimmune patients in the settings of acute and chronic inflammation driven by vaccination, infection, autoimmunity and aging, are formed in an IFNγ-dependent manner and likely represent a pool of primary and secondary pre-ASCs as well as effector memory B cells that are epigenetically poised to differentiate.

The IFNγ-induced T-bet^hi^IRF4^int^ pre-ASC population that we characterized in our *in vitro* studies is similar to the T-bet^hi^ DN2 subset that is expanded in SLE patients. Since the expansion of the T-bet^hi^ DN2 cells in SLE patients correlates with systemic levels of IFNγ and IFNγ-induced cytokines, we postulate that the DN2 cells likely arise in an IFNγ-dependent fashion in these patients. In support of this possibility, we demonstrate that the IFNγ-directed changes in chromatin accessibility within the *IL21R* and *PRDM1* loci seen in the *in vitro* generated T-bet^hi^IRF4^int^ pre-ASCs are also found in T-bet^hi^ DN2 cells isolated from SLE patients. Moreover, we show that the molecular properties of the SLE DN2 subset and the *in vitro* generated IFNγ-dependent T-bet^hi^ B~DN~ cells are similar and unique when compared to conventional memory B cells or B~N~ cells. For example, as discussed above, IFNγ primes the T-bet^hi^ B~DN~ cells to respond to subthreshold concentrations of R848. Similarly, SLE DN2 cells make augmented responses to TLR7/8-stimulation compared to other B cell subsets ([@bib24]). We also show that SLE patient DN2 pre-ASCs and the *in vitro* generated T-bet^hi^ B~DN~ subset can differentiate without a need for additional BCR stimulation. This is similar to memory B cells but unlike what we find for B~N~ cells. However, like B~N~ cells ([@bib12]), both the SLE DN2 subset ([@bib65]; [@bib24]) and the *in vitro* generated T-bet^hi^ B~DN~ subset require IL-21 to differentiate into ASCs. Thus, given the many shared phenotypic, molecular and functional properties of the *in vitro* generated T-bet^hi^ B~DN~ subset and the T-bet^hi^ DN2 cells found in SLE patients, we think that the *in vitro* pre-ASC cultures described here could be used to better understand the development, maintenance and functional attributes of the T-bet^hi^ DN2 cells that are expanded and associated with more severe disease in SLE patients.

In summary, we demonstrate that IFNγ is critical for the *in vitro* formation of a T-bet^hi^IRF4^int^ pre-ASC population that is remarkably similar to the T-bet^hi^ DN2 cells that accumulate in SLE patients who present with high autoAb titers, elevated disease activity and increased systemic levels of IFNγ. We show that IFNγ signals, particularly when combined with IL-2 and TLR7/8 + BCR ligands, initiate epigenetic reprogramming of human B cells -- changes which poise the activated B~N~ cells to respond to IL-21 and fully commit to the ASC lineage. Based on these results, we argue that blocking IFNγ signaling in SLE patients should curtail development of T-bet^hi^ DN2 pre-ASCs from primary B~N~ cells, which would result in decreased autoAb production and reduced disease activity. However, results from a phase I trial examining IFNγ blockade in SLE patients did not reveal a therapeutic benefit ([@bib6]). Interestingly, no African Americans SLE patients with nephritis were included in the study ([@bib6]). Given the data showing that T-bet^hi^ DN2 cells are most expanded in African American patients with severe disease ([@bib65]; [@bib24]) and our data presented here showing that the DN2 cells likely develop in response to IFNγ, we propose that future studies evaluating the efficacy of IFNγ blockade in SLE patients should focus specifically on the subset of patients who present with elevated IFNγ levels and significant expansion of the IFNγ-inducible T-bet expressing DN2 pre-ASC population.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                      Designation                                                                           Source or reference                      Identifiers     Additional information
  (species) or resource                                                                                                                                                                             
  -------------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------------- --------------- ------------------------
  **Commercial Assays or Kits**                                                                                                                                                                     

  Commercial assay or kit                            Human Anti-SM IgG ELISA Kit                                                           Alpha Diagnostic International           3300--100-SMG   

  Commercial assay or kit                            Milliplex MAP Human\                                                                  Millipore                                HCYTOMAG-60K    
                                                     Cytokine/Chemokine Magnetic Bead Panel                                                                                                         

  Commercial assay or kit                            Milliplex MAP Human Th17 Magnetic Bead Panel                                          Millipore                                HTH17MAG-14K    

  Commercial\                                        Fixable Aqua Dead Cell Stain Kit                                                      Life Technologies                        34966           
  assay or kit                                                                                                                                                                                      

  Commercial assay or kit                            CellTrace Violet                                                                      Invitrogen by Thermo Fisher Scientific   C34557          

  Commercial assay or kit                            Transcription Factor PhosphoPlus Buffer Set                                           BD Pharmingen                            565575          

  Commercial assay or kit                            Foxp3/Transcription Factor Staining Buffer Set                                        eBioscience                              00-5523-00      

  Commercial assay or kit                            EasySep Human Naïve B Cell Enrichment Set                                             STEMCELL Technologies                    19254           

  Commercial assay or kit                            EasySep Human Naïve CD4 + T Cell Isolation Kit                                        STEMCELL\                                19155           
                                                                                                                                           Technologies                                             

  Commercial assay or kit                            Anti-IgD Microbeads human                                                             Miltenyi Biotec                          130-103-775     

  Commercial assay or kit                            HA, Sterile Clear Plates 0.45microm Surfactant-Free, Mixed Cellulose Ester Membrane   Millipore                                MAHAS4510       

  **Cytokines For Culture**                                                                                                                                                                         

  Peptide,\                                          Recombinant Human IFN-gamma                                                           R&D                                      285-IF          20 ng/ml
  recombinant protein                                                                                                                                                                               

  Peptide, recombinant protein                       Recombinant Human IL4                                                                 R&D                                      204-IL          20 ng/ml

  Peptide,\                                          Recombinant Human IL12                                                                R&D                                      219-IL          1 ng/ml
  recombinant\                                                                                                                                                                                      
  protein                                                                                                                                                                                           

  Peptide, recombinant protein                       Recombinant Human IL21                                                                Peprotech                                200--21         10 ng/ml

  Peptide, recombinant protein                       Recombinant Human BAFF                                                                Peprotech                                310--13         10 ng/ml

  Peptide, recombinant protein                       Recombinant Human IL2                                                                 Peprotech                                200--02         50 U/ml

  **Chemical Compounds/Drugs For Culture or Flow**                                                                                                                                                  

  Chemical compound, drug                            R848                                                                                  InvivoGen                                tlrl-r848       5 microgram/ml

  Chemical compound, drug                            Iscove\'s DMEM, 1X                                                                    Corning Mediatech                        10--016-CV      

  Chemical compound, drug                            RPMI-1640                                                                             Lonza                                    12--702F        

  Chemical compound, drug                            MEM Nonessential Amino Acids                                                          Corning Mediatech                        25--025 Cl      

  Chemical compound, drug                            Sodium Pyruvate100 mM Solution                                                        GE Life sciences                         SH30239.01      

  Chemical compound, drug                            Penicillin Streptomycin Solution                                                      Corning                                  30--002 Cl      

  Chemical compound, drug                            Gentamicin                                                                            Gibco                                    15750--060      

  Chemical compound, drug                            7-amino-AMD                                                                           Calbiochem                               129935          

  Chemical compound, drug                            Fluoresbrite Carboxylate YG 10 micron Microspheres                                    Polysciences                             18142           

  Chemical compound, drug                            DPBS, 1X                                                                              Corning Mediatech                        21--031-CV      

  Chemical compound, drug                            EDTA                                                                                  Thermo Fisher Scientific                 15575--038      

  Chemical compound, drug                            HEPES Buffer1M Solution                                                               Corning Mediatech                        25--060 Cl      

  **Chemical Compounds/Drugs For ELISPOT**                                                                                                                                                          

  Chemical compound,\                                BCIP/NBT Alkaline Phosphatase Substrate/membrane                                      Moss, Inc                                NBTM-1000       
  drug                                                                                                                                                                                              

  **Antibodies For Culture**                                                                                                                                                                        

  Antibody                                           Purified\                                                                             Biolegend                                300414          5 microgram/ml
                                                     anti-human\                                                                                                                                    
                                                     CD3 (mouse IgG1)                                                                                                                               

  Antibody                                           Purified anti-human CD28 (mouse IgG1)                                                 Biolegend                                302914          5 microgram/ml

  Antibody                                           Human IL-12\                                                                          R&D                                      AB-219-NA       10 microgram/ml
                                                     Antibody (goat IgG)                                                                                                                            

  Antibody                                           Human IFN-gamma Antibody (goat IgG)                                                   R&D                                      AB-285-NA       10 microgram/ml

  Antibody                                           Human IL-4\                                                                           R&D                                      AB-204-NA       10 microgram/ml
                                                     Antibody (goat IgG)                                                                                                                            

  Antibody                                           AffiniPure F(ab\')₂ Fragment Goat Anti-Human IgM, Fcμ fragment specific               Jackson ImmunoResearch                   109-006-129     5 microgram/ml

  Antibody                                           AffiniPure F(ab\')₂ Fragment Goat Anti-Human IgG, F(ab\')₂ fragment specific          Jackson ImmunoResearch                   109-006-097     5 microgram/ml

  Antibody                                           AffiniPure F(ab\')₂ Fragment Goat Anti-Human Serum IgA, α chain specific              Jackson ImmunoResearch                   109-006-011     5 microgram/ml

  **Antibodies For ELISPOT**                                                                                                                                                                        

  Antibody                                           AffiniPure Goat Anti-Human\                                                           Jackson ImmunoResearch                   109-005-088     2 microgram/ml
                                                     IgG (H + L)                                                                                                                                    

  Antibody                                           Alkaline Phosphatase AffinitiPure F(ab\')2\                                           Jackson ImmunoResearch                   109-056-098     (1:1000)
                                                     Fragment Goat, Anti-Human IgG, Fc-gamma Fragment Specific                                                                                      

  **Others For Culture**                                                                                                                                                                            

  Other                                              Human Serum AB                                                                        GemCell                                  100--512        

  Other                                              Fetal Bovine Serum                                                                    Biowest                                  S1690           

  **Antibodies For Flow**                                                                                                                                                                           

  Antibody                                           Fitc Mouse Anti-Human **CD3** (clone **HIT3a**)                                       BD Biosciences                           555339          (1:200)

  Antibody                                           PercP/Cy5.5 Mouse Anti-Human **CD3** (clone **OKT3**)                                 eBioscience                              45-0037-71      (1:200)

  Antibody                                           Fitc Mouse Anti-Human\                                                                eBioscience                              11-0048-80      (1:400)
                                                     **CD4** (clone **OKT4**)                                                                                                                       

  Antibody                                           PE Mouse Anti-Human\                                                                  Biolegend                                317410          (1:200)
                                                     **CD4** (clone **OKT4**)                                                                                                                       

  Antibody                                           PercP/Cy5.5 Mouse\                                                                    eBioscience                              45-0048-42      (1:200)
                                                     Anti-Human**CD4** (clone **OKT4**)                                                                                                             

  Antibody                                           BV510 Mouse Anti-Human **CD4** (clone **OKT4**)                                       Biolegend                                317444          (1:100)

  Antibody                                           Fitc Mouse Anti-Human**CD11c** (clone **Bu15**)                                       Biolegend                                337214          (1:200)

  Antibody                                           PE Mouse Anti-Human\                                                                  Biolegend                                337205          (1:400)
                                                     **CD11c** (clone **Bu15**)                                                                                                                     

  Antibody                                           PercP/Cy5.5 Mouse\                                                                    Biolegend                                325621          (1:200)
                                                     Anti-Human **CD14** (clone **HCD14**)                                                                                                          

  Antibody                                           Fitc Mouse Anti-Human\                                                                Miltenyi                                 302256          (1:100)
                                                     **CD19** (clone **LT19**)                                                                                                                      

  Antibody                                           PE Mouse\                                                                             Biolegend                                302208          (1:200)
                                                     Anti-Human **CD19** (clone **HIB19**)                                                                                                          

  Antibody                                           PercP/Cy5.5 Mouse Anti-Human\                                                         Biolegend                                302230          (1:100)
                                                     **CD19** (clone **HIB19**)                                                                                                                     

  Antibody                                           APC Mouse Anti-Human\                                                                 BD Pharmingen                            555415          (1:200)
                                                     **CD19** (clone **HIB19**)                                                                                                                     

  Antibody                                           APC-H7 Mouse Anti-Human **CD19** (clone **HIB19**)                                    BD Pharmingen                            560727          (1:100)

  Antibody                                           BV421 Mouse Anti-Human **CD19** (clone **HIB19**)                                     Biolegend                                302234          (1:200)

  Antibody                                           V500 Mouse\                                                                           BD Horizon                               561121          (1:100)
                                                     Anti-Human **CD19** (clone **HIB19**)                                                                                                          

  Antibody                                           PercP/Cy5.5 Mouse Anti-Human **CD21** (clone **Bu32**)                                Biolegend                                354908          (1:100)

  Antibody                                           Fitc Mouse Anti-Human **CD23** (clone **M-L23.4**)                                    Miltenyi                                 130-099-365     (1:100)

  Antibody                                           PE Mouse Anti-Human\                                                                  Biolegend                                338507          (1:200)
                                                     **CD23** (clone **EBVCS-5**)                                                                                                                   

  Antibody                                           APC Mouse\                                                                            BD Pharmingen                            558690          (1:200)
                                                     Anti-Human\                                                                                                                                    
                                                     **CD23** (clone **M-L233**)                                                                                                                    

  Antibody                                           Fitc Mouse Anti-Human **CD27** (clone **M-T271**)                                     Biolegend                                356404          (1:100)

  Antibody                                           PercP/Cy5.5 Mouse Anti-Human **CD27** (clone **M-T271**)                              Biolegend                                356408          (1:100)

  Antibody                                           APC Mouse Anti-Human **CD27** (clone **M-T271**)                                      Biolegend                                356410          (1:200)

  Antibody                                           APC-H7 Mouse Anti-Human\                                                              eBioscience                              560222          (1:100)
                                                     **CD27** (clone **M-T271**)                                                                                                                    

  Antibody                                           BV421 Mouse Anti-Human **CD27** (clone **M-T271**)                                    Biolegend                                356418          (1:200)

  Antibody                                           PE/Cy7 Mouse Anti-Human**CD38** (clone **HIT2**)                                      eBioscience                              25-0389-42      (1:1200)

  Antibody                                           PercP/Cy5.5\                                                                          Biolegend                                362505          (1:100)
                                                     Mouse Anti-Human**CD56** (clone **5.IH11**)                                                                                                    

  Antibody                                           PE Mouse Anti-Human **FcRL5** (clone **509** F6)                                      Biolegend                                340304          (1:200)

  Antibody                                           eFluor660 Mouse Anti-Human\                                                           eBioscience                              50-3078-42      (1:200)
                                                     **FcRL5** (clone **509** F6)                                                                                                                   

  Antibody                                           APC Mouse Anti-Human**FcRL5** (clone **509** F6)                                      Biolegend                                340306          (1:200)

  Antibody                                           PE Mouse Anti-Human**CXCR3** (clone **CEW33D**)                                       eBioscience                              12-1839-42      (1:200)

  Antibody                                           PE Mouse Anti-Human**CXCR3** (clone **49801**)                                        R&D                                      FAB160P         (1:200)

  Antibody                                           Fitc Mouse Anti-Human**CXCR5** (clone **J252D4**)                                     Biolegend                                356914          (1:100)

  Antibody                                           PE Mouse Anti-Human **CXCR5** (clone **J252D4**)                                      Biolegend                                356904          (1:200)

  Antibody                                           PercP-Cy5.5 Mouse Anti-Human **CXCR5** (clone **J252D4**)                             Biolegend                                356910          (1:100)

  Antibody                                           APC Mouse Anti-Human **CXCR5** (clone **J252D4**)                                     Biolegend                                356907          (1:200)

  Antibody                                           BV421 Mouse Anti-Human**CXCR5** (clone **J252D4**)                                    Biolegend                                356920          (1:200)

  Antibody                                           Fitc Mouse Anti-Human**IgD** (clone **IgD26**)                                        Miltenyi                                 130-099-633     (1:100)

  Antibody                                           Fitc Mouse Anti-Human **IgD** (clone **IA6-2**)                                       BD Pharmingen                            555778          (1:100)

  Antibody                                           BV421 Mouse Anti-Human **IgD** (clone **IA6-2**)                                      Biolegend                                348226          (1:200)

  Antibody                                           BV510 Mouse Anti-Human**IgD** (clone **IA6-2**)                                       BD Horizon                               561490          (1:100)

  Antibody                                           APC Mouse Anti-Human**IgM** (clone **MHM-88**)                                        Biolegend                                314509          (1:200)

  Antibody                                           Fitc Mouse\                                                                           Miltenyi                                 130-099-229     (1:200)
                                                     Anti-Human **IgG** (clone **IS11-3B2.2.3**)                                                                                                    

  Antibody                                           PE Mouse Anti-Human**IgG** (clone **IS11-3B2.2.3**)                                   Miltenyi                                 130-099-201     (1:200)

  Antibody                                           PE Mouse Anti-Human**IgA(1)** (clone **IS11-8E10**)                                   Miltenyi                                 130-099-108     (1:200)

  Antibody                                           PE Mouse Anti-Human**IgA(2**) (clone **IS11-21E11**)                                  Miltenyi                                 130-100-316     (1:200)

  Antibody                                           Fitc Mouse Anti-Human/Mouse**T-bet** (clone **4B10**)                                 Biolegend                                644812          (1:100)

  Antibody                                           APC Mouse Anti-Human/Mouse**T-bet** (clone **4B10**)                                  Biolegend                                644814          (1:100)

  Antibody                                           AF488 Mouse Anti-Human/Mouse **GATA** (clone **L50-823**)                             BD Pharmingen                            560163          (1:100)

  Antibody                                           PE Rat\                                                                               BD Pharmingen                            564702          (1:200)
                                                     Anti-Human/Mouse**Blimp-1** (clone **6D3**)                                                                                                    

  Antibody                                           PE Rat Anti-Human/Mouse **IRF4** (clone **IRF4.3E4**)                                 Biolegend                                646403          (1:600)

  Antibody                                           APC Mouse Anti-Human **IL21** (clone **3A3-N2**)                                      Biolegend                                513007          (1:100)

  Antibody                                           APC Mouse Anti-Human**IL21R** (clone **2** G1-K12)                                    Biolegend                                347807          (1:50)

  Antibody                                           BV421 Mouse Anti-Human/Mouse**pSTAT3** (clone **13A3-1**)                             Biolegend                                651009          (1:100)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Human Subjects and samples {#s4-1}
--------------------------

The UAB and Emory Human Subjects Institutional Review Board approved all study protocols for HD (UAB) and SLE patients (UAB and Emory). All subjects gave written informed consent for participation and provided peripheral blood for analysis. SLE patients were recruited in collaboration with the outpatient facilities of the Division of Rheumatology and Clinical Immunology at UAB or the Division of Rheumatology at Emory. UAB and Emory SLE patients met a minimum of three ACR criteria for the classification of SLE. HDs were self-identified and recruited through the UAB Center for Clinical and Translational Science and the Alabama Vaccine Research Center (AVCR). The UAB Comprehensive Cancer Center Tissue Procurement Core Facility provided remnant tonsil tissue samples from patients undergoing routine tonsillectomies.

Lymphocyte and plasma isolation {#s4-2}
-------------------------------

Peripheral blood (PB) from human subjects was collected in K2-EDTA tubes (BD Bioscience). Human tonsil tissue was dissected, digested for 30 min at 37°C with DNAse (150 U/ml, Sigma) and collagenase (1.25 mg/ml, Sigma), and then passed through a 70 μm cell strainer (Falcon). Human PBMCs and plasma from blood samples and low-density tonsil mononuclear cells were separated by density gradient centrifugation over Lymphocyte Separation Medium (CellGro). Red blood cells were lysed with Ammonium Chloride Solution (StemCell). Plasma was fractionated in aliquots and stored at −80°C. Human PBMCs and tonsil mononuclear cells were either used immediately or were cryopreserved at −150°C.

Human lymphocyte purification {#s4-3}
-----------------------------

Naïve CD4^+^ T cells and CD19^+^ B cells were isolated from human PBMCs or tonsils using EasySep enrichment kits (StemCell). B~N~ cells were then positively selected using anti-IgD microbeads (Miltenyi). B cell subsets were sort-purified from PBMCs and tonsils as described in text.

Generation of Th1 and Th2 cells {#s4-4}
-------------------------------

Polarized CD4^+^ effector T cells were generated by activating purified HD naïve CD4 T cells with plate-bound anti-CD3 (UCHT1) and anti-CD28 (CD28.2) (both 5 μg/ml, Biolegend) in the presence of IL-2 (50 U/ml), IL-12 (1 ng/ml) and anti-IL4 (10 μg/ml) (Th1 conditions) or IL-2 (50 U/ml), IL-4 (20 ng/ml), anti-IL12 (10 μg/ml) and anti-IFNγ (10 μg/ml) (Th2 conditions). Cells were transferred into fresh media on day 3 and IL-2 was added, as needed. Cells were re-activated every 7 days using the same cultures conditions for 3 rounds of polarization. All cytokines and Abs except IL-2 (Peprotech) were purchased from R and D and T cell polarizing media contained Iscove's DMEM supplemented with penicillin (200 μg/ml), streptomycin (200 μg/ml), gentamicin (40 μg/ml), 10% FBS and 5% human serum blood type AB.

T/B co-cultures {#s4-5}
---------------

Purified B cell subsets from HD or SLE patients were co-cultured in B cell media in the presence of IL-2 (50 U/ml)±IL-21 (10 ng/ml) with allogeneic *in vitro* generated Th1 or Th2 effectors (0.6 × 10^6^ cells/ml, ratio 5B:1T) for 5--6 days, as indicated. B cell media contained Iscove's DMEM supplemented with penicillin (200 μg/ml), streptomycin (200 μg/ml), gentamicin (40 μg/ml), 10% FBS, and insulin (5 μg/ml; Santa Cruz Biotechnology).

B cell activation with defined stimuli {#s4-6}
--------------------------------------

Purified B cell subsets isolated from the tonsil or blood of HD or SLE patients were cultured (1 × 10^6^ cells/ml) for 3 days with 5 μg/ml anti-Ig (Jackson ImmunoResearch), 5 μg/ml R848 (InvivoGen), 50 U/ml IL-2, 10 ng/ml BAFF, 10 ng/ml IL-21 (Peprotech) and 20 ng/ml IFNγ (R and D) (Step 1). Cells were either directly analyzed or washed and recultured (2 × 10^5^ cells/ml) for an additional 3 days with the same stimuli (Step 2). The number of ASCs and total cells recovered in cultures on day 6 were determined and then normalized based on cell input. In some experiments, anti-Ig, R848, IL-21, IL-2, IFNγ or BAFF were omitted from the cultures during Step 1, or Step 2 or both steps. In other experiments, the concentration of R848 in Step 1 and Step 2 and/or the concentration of IFNγ in Step1 was varied, as indicated in the text. In some experiments, B cell subsets isolated from blood of SLE patients and HD were stimulated for 2.5--6 days with R848 and IL-21, IL-2, BAFF and IFNγ.

STAT3 phosphorylation assays {#s4-7}
----------------------------

HD B~N~ cells were cultured with 5 μg/ml anti-Ig and 5 μg/ml R848 alone (Be.0) or in combination with IFNγ (Be.IFNγ), IL2 (Be.IL2), or IL2 plus IFNγ (Be.γ2). On day 3 cells were washed and restimulated with medium alone or with IL-21 (10 ng/ml) for 20 min at 37°C. The cells were fixed and permeabilized with BD Transcription Factor Phospho Buffer Set and intracellular staining with anti phospho-STAT3 was performed.

*In vitro* B cell proliferation {#s4-8}
-------------------------------

Purified B cell subsets (1−5 × 10^6^ cells/ml) were stained for 10 min at 37°C with PBS diluted CellTrace Violet (Molecular Probes, Thermofisher). The cells were washed and either used in T effector co-culture experiments or were cultured in the presence of defined stimuli.

*In vitro* ASC differentiation {#s4-9}
------------------------------

B~N~ cells were co-cultured with *in vitro* generated Th1 or Th2 cells plus IL-2 and IL-21. On day 6 of the co-culture B~DN~ cells from both cultures were sort-purified and then cultured in 0.22μM-filtered conditioned media (media collected from the original T/B co-cultures). ASCs were enumerated after 18 hr by flow cytometry.

Cytokine measurements {#s4-10}
---------------------

Th1 and Th2 cells were restimulated with platebound anti-CD3 and anti-CD28 (both 5 μg/ml). Cytokine levels in restimulated T cell cultures and SLE patient plasma samples was measured using Milliplex MAG Human Cytokine/Chemokine Immunoassays (Millipore).

Elispot {#s4-11}
-------

Serial diluted B cells were transferred directly to anti-IgG (Jackson ImmunoResearch) coated ELISPOT plates (Millipore) for 6 hr. Bound Ab was detected with alkaline phosphatase-conjugated anti-human IgG (Jackson ImmunoResearch) followed by development with alkaline phosphatase substrate (Moss, Inc). ELISPOTs were visualized using a CTL ELISPOT reader. The number of spots detected per well (following correction for non-specific background) was calculated.

Anti-SMITH ELISAs {#s4-12}
-----------------

Anti-Smith IgG autoantibodies in plasma from SLE patients and healthy donors were detected using the enzymatic immunoassay kit (Alpha Diagnostic) according to the manufacturer protocol.

Flow cytometry {#s4-13}
--------------

Single cell suspensions were blocked with 10 μg/ml FcR blocking mAb 2.4G2 (mouse cells) or with 2% human serum or human FcR blocking reagent (Miltenyi) (human cells) and then stained with fluorochrome-conjugated Abs. 7AAD or LIVE/DEAD Fixable Dead Cell Stain Kits (Molecular Probes/ThermoFisher) were used to identify live cells. For intracellular staining, cells were stained with Abs specific for cell surface markers, fixed with formalin solution (neutral buffered, 10%; Sigma) and permeabilized with 0.1% IGEPAL (Sigma) in the presence of Abs. Alternatively, the transcription factor and phospho-transcription factor staining buffers (eBioscience) were used. Stained cells were analyzed using a FACSCanto II (BD Bioscience). Cells were sort-purified with a FACSAria (BD Biosciences) located in the UAB Comprehensive Flow Cytometry Core. Analysis was performed using FlowJo v9.9.3 and FlowJo v10.2.

RNA-seq library preparation and analysis {#s4-14}
----------------------------------------

RNA samples were isolated from TRIzol (FisherThermo) treated sort-purified day 6 Be1 and Be2 IgD^neg^CD27^neg^ B cells. 300 ng of total RNA from 3 biological replicates per B cell subset was used as input for the KAPA stranded mRNA-seq Kit with mRNA capture beads (KAPA Biosystems). Libraries were assessed for quality on a bioanalyzer, pooled, and sequenced using 50 bp paired-end chemistry on a HiSeq2500. Sequencing reads were mapped to the hg19 version of the human genome using TopHat with the default settings and the hg19 UCSC KnownGene table as a reference transcriptome. For each gene, the overlap of reads in exons was summarized using the GenomicRanges package in R/Bioconductor. Genes that contained two or more reads in at least 3 samples were deemed expressed (11598 of 23056) and used as input for edgeR to identify differentially expressed genes (DEGs). *P*-values were false-discovery rate (FDR) corrected using the Benjamini-Hochberg method and genes with a FDR of \<0.05 were considered significant. Expression data was normalized to reads per kilobase per million mapped reads (FPKM). Data processing and visualization scripts are available ([@bib53]; [@bib54]; [@bib55]; copies archived at [https://github.com/elifesciences-publications/genomePlots, ](https://github.com/elifesciences-publications/genomePlots)<https://github.com/elifesciences-publications/heatmap>, and <https://github.com/elifesciences-publications/plotScaledBEDfeatures> respectively). All RNA-seq data is available from the GEO database under the accession GSE95282. See also [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

ATAC-seq preparation and analysis {#s4-15}
---------------------------------

ATAC-seq data generated from the SLE B cell subsets was previously reported ([@bib24]). ATAC-seq analysis on *in vitro* generated B cell was performed on 10,000 Be.0, Be.IFNγ, Be.IL2 or Be.γ2 cells as previously described ([@bib52]). Sorted cells were resuspended in 25 μl tagmentation reaction buffer (2.5 μl Tn5, 1x Tagment DNA Buffer, 0.2% Digitonin) and incubated for 1 hr at 37°C. Cells were lysed with 25 μl 2x Lysis Buffer (300 mM NaCl, 100 mM EDTA, 0.6% SDS, 1.6 μg Proteinase-K) for 30 min at 40°C, low molecular weight DNA was purified by size-selection with SPRI-beads (Agencourt), and then PCR amplified using Nextera primers with 2x HiFi Polymerase Master Mix (KAPA Biosystems). Amplified, low molecular weight DNA was isolated using a second SPRI-bead size selection. Libraries were sequenced using a 50 bp paired-end run at the NYU Genome Technology Center. Raw sequencing reads were mapped to the hg19 version of the human genome using Bowtie ([@bib29]) with the default settings. Duplicate reads were marked using the Picard Tools MarkDuplicates function (<http://broadinstitute.github.io/picard/>) and eliminated from downstream analyses. Enriched accessible peaks were identified using MACS2 ([@bib68]) with the default settings. Differentially accessible regions were identified using edgeR v3.18.1 ([@bib45]) and a generalized linear model. Read counts for all peaks were annotated for each sample from the bam file using the Genomic Ranges ([@bib31]) R/Bioconductor package and normalized to reads per million (rpm) as previously described ([@bib52]). Peaks with a greater than 2-fold change and FDR \< 0.05 between comparisons were termed significant. Genomic and motif annotations were computed for ATAC-seq peaks using the HOMER ([@bib20]) annotatePeaks.pl script. The findMotifsGenome.pl function of HOMER v4.8.2 (42) was used to identify motifs enriched in DAR and the 'de novo' output was used for downstream analysis. To generate motif footprints, the motifs occurring in peaks were annotated with the HOMER v4.8.2 annotatePeaks.pl function ([@bib20]) using the options '-size given'. The read depth at the motif and surrounding sequence was computed using the GenomicRanges v1.22.4 (66) package and custom scripts in R/Bioconductor. All other analyses and data display were performed using R/Bioconductor with custom scripts ([@bib53]; [@bib54]; [@bib55]). ATAC-seq data has been deposited in the NCBI GEO database under accession number GSE119726. See also [Supplementary files 3](#supp3){ref-type="supplementary-material"}--[5](#supp5){ref-type="supplementary-material"} for complete list of DAR and for analysis of TF motif enrichment in the ATAC-seq dataset.

GSEA {#s4-16}
----

For gene set enrichment analysis samples were submitted to the GSEA program (<http://software.broadinstitute.org/gsea/index.jsp>). For the comparison of interest (i.e., B~DN~ Be1 and B~DN~ Be2 cells), all detected genes were ranked by multiplying the -log~10~ of the P-value from edgeR by the sign of the fold change and used as input for the GSEA Preranked analysis. The custom gene set defining genes upregulated in SLE T-bet^hi^ B~DN~ relative to other B cell subsets were derived from [@bib24] and are listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.

Ingenuity Pathway Analysis (IPA) {#s4-17}
--------------------------------

IPA upstream regulator analysis ([@bib28], Qiagen, Redwood City CA) was performed using the log~2~ fold-change in gene expression between genes that were significantly differentially expressed (FDR \< 0.05) in B~DN~ Be1 and B~DN~ Be2 cells. Upstream regulators with an activation z-score of ≥2 or ≤ −2 were considered to be activated or inhibited in B~DN~ Be1 cells. Overlap *P*-value (between the regulator's downstream target list and the DEG list was based on Fisher's exact test.

Statistical analysis {#s4-18}
--------------------

Comparisons between two groups were performed with the Student's *t* test for normally distributed variables and the Mann-Whitney test for non-normally distributed variables. The one-way ANOVA test was used to compare mean values of 3 or more groups and the Kruskal-Wallis nonparametric test was used to compare medians. Strength and direction of association between two variables measures was performed using the D'Agostino-Pearson normality test followed by Pearson's or Spearman's correlation test. Data were considered significant when p≤0.05. Analysis of the data was done using the GradhPad Prism version 7.0a software (GraphPad). See [Supplementary file 5](#supp5){ref-type="supplementary-material"} for all statistical comparisons.

Mice and bone marrow chimeras {#s4-19}
-----------------------------

All experimental animals were bred and maintained in the UAB animal facilities. All procedures involving animals were approved by the UAB Institutional Animal Care and Use Committee and were conducted in accordance with the principles outlined by the National Research Council. B6.SB-*Yaa*/J.B6;129S-*Fcgr2b^tm1Ttk^*/J (Yaa.*Fcgr2b*^-/-^) ([@bib42]) (obtained by permission from Dr. Sylvia Bolland (NIH)) were intercrossed with B6.129S2-Ighm^tm1Cgn^/J (μMT) or B6.129S6-*Tbx21*^tm1Glm^/J (*Tbx21*^-/-^) mice (both strains obtained from Jackson Laboratory) to produce B cell deficient (Yaa.*Fcgr2b*^-/-^.μMT) or T-bet deficient (Yaa.*Fcgr2b*^-/-^.*Tbx21*^-/-^) lupus-prone mice. To generate bone marrow chimeras, μMT recipient mice were irradiated with 950 Rads from a high-energy X-ray source, delivered in a split dose 4 hr apart. Recipients were reconstituted (10^7^ total BM cells) with 80% Yaa.*Fcgr2b*^-/-^.μMT BM +20% Yaa.*Fcgr2b*^-/-^.*Tbx21*^-/-^ BM (B-YFT chimeras) or with 80% Yaa.*Fcgr2b*^-/-^ BM +20% Yaa.*Fcgr2b*^-/-^.*Tbx21*^-/-^ BM (20%Control chimeras).

Mouse ANA detection and imaging {#s4-20}
-------------------------------

Antinuclear antibodies (ANA) were detected by an indirect immunofluorescence assay using HEp-2 cells. Fixed HEp-2-coated microscope slides (Kallestad, BioRad) were blocked, incubated with serum diluted 1:100 and stained with anti-IgG-FITC (Southern Biotech) (10 μg/ml). Slides were mounted with SlowFade Gold Antifade Mountant with DAPI (ThermoFisher) and imaged. Anti-nuclear staining was quantitated as the mean flourescence intensity (MFI) of IgG-FITC over DAPI-staining areas (nuclei) using NIS-Elements AR software (Nikon). Data are presented as log nuclear IgG MFI normalized by subtracting the MFI of negative control serum from B6 mice. ANA images were collected using a Nikon Eclipse Ti inverted microscope and recorded with a Clara interline CCD camera (Andor). The images were taken with a 20X (immunofluorescence) objective for 200-400X final magnification. Images were collected using NIS Elements software, scale bars were added and images were saved as high-resolution JPEGs. JPEG images were imported into Canvas Ver 12 software and were resized, cropped with the identical settings applied to all immunofluorescence images from the same experiment. Final images presented at 600--650 dpi (ANA).

Urinary Albumin to Creatinine Ratio (UACR) {#s4-21}
------------------------------------------

Albumin concentrations in urine samples, collected from live or euthanized mice, were measured using the Mouse Albumin ELISA Quantitation Set (Bethyl Labs) according to manufacturer's protocol using a mouse reference serum as an albumin standard. To normalize for urine concentration, urinary creatinine was measured by liquid chromatography-mass spectrometry in the UAB/UCSD O\'Brien Core Center for Acute Kidney Injury Research. The UACR was calculated as μg/ml albumin divided by mg/ml creatinine and is reported as μg albumin/mg creatinine.
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###### RNA-seq analysis of *in vitro* generated IgD^neg^CD27^neg^ B~DN~ Be1 and Be2 cells.

RNA-seq analysis of sorted IgD^neg^CD27^neg^ B~DN~ Be1 and Be2 cells isolated from Th1/B~N~ and Th2/B~N~ co-cultures. Data are shown as rpkm values from 3 independent Be1 and Be2 co-cultures that were set up with donor-matched sets of allogeneic B~N~ cells and *in vitro* polarized Th1 or Th2 cells. Log2 fold change (Be1/Be2), *P* and FDR values reported.

10.7554/eLife.41641.024

###### Up DEG list from T-bet expressing B~DN~ cells from SLE patients.

RNA-seq analysis was previously performed ([@bib24]) on sort-purified T-bet^hi^-expressing IgD^neg^CD27^neg^IgG^+^CXCR5^neg^ B cells from HD and SLE patients (DN2 cells). The DN2 Up DEG list is defined as genes that are significantly upregulated in SLE and HD DN2 cells relative to at least one other B cell subset (B~N~, switched memory or CXCR5-expressing (T-bet^lo^) DN1 memory = cells).

10.7554/eLife.41641.025

###### ATAC-seq data set from day 3 Be.0, Be.IFNγ, Be.IL2 and Be.γ2 B cell subsets.

HD B~N~ cells were activated for 3 days with anti-Ig and R848 alone (Be.0) or in combination with: IFNγ (Be.IFNγ), IL-2 (Be.IL2) or both IFNγ+IL-2 (Be.γ2). ATAC-seq analysis was performed on DNA isolated from each B cell subset. Table includes all identified differentially accessible regions (DAR) with fold change and FDR *q* values for each comparison. N = 2 independent samples/group.

10.7554/eLife.41641.026

###### *P* values for ATAC-seq motif enrichment comparisons.

*P* values for chromatin accessibility at transcription factor consensus DNA binding motifs (T-bet, IRF4, BLIMP1, NF-kB p65 and NF-kB REL) in ATAC-seq data. Comparisons include two-sided Student's t-test comparisons with data from day 3 Be.0, Be.IFNγ, Be.IL2 and Be.γ2 cells.

10.7554/eLife.41641.027

###### Complete statistical information for all data presented in this manuscript.

10.7554/eLife.41641.028

Data availability {#s7}
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Sequencing data have been deposited in GEO under accession codes GSE95282 and GSE118984. All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files for sequencing analysis are included as Supplementary Files 1 and 2 (excel files).

The following datasets were generated:

LundFEScharerCD2018Chromatin accessibility of ex vivo derived Be-g2 cellsNCBI Gene Expression OmnibusGSE119726

LundFEScharerCD2018Be1 and Be2 B cells are transcriptionally distinctNCBI Gene Expression OmnibusGSE95282

The following previously published datasets were used:

SanzIJenksSMarigortaUM2018Gene expression studies of lupus and healthy B cell subsets through RNA sequencingNCBI Gene Expression OmnibusGSE92387

10.7554/eLife.41641.040

Decision letter

Batista

Facundo D

Reviewing Editor

Ragon Institute of MGH, MIT and Harvard

United States

Gaya

Mauro

Reviewer

Centre d\'immunologie de Marseille-Luminy

France

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Differentiation of human T-bet^hi^ B cells is controlled by IFNγ-dependent epigenetic regulation of IL21R\" for consideration by *eLife*. Your article has been reviewed by Tadatsugu Taniguchi as the Senior Editor, a Reviewing Editor, and three reviewers. The following individual involved in review of your submission has agreed to reveal their identity: Mauro Gaya (Reviewer \#1).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As you might see from the reviews comments there has been some disagreement about the novelty of the work. Nevertheless, after discussion with the reviewers, we have decided to consider a revised version of the manuscript in which a considerable effort needs to be focused in incorporations their comments and most importantly streamline the main message of the manuscript. We have decided to copy all reviewers comments to assist you with this. In your revised manuscript it will be important to discuss the novelty of the work in in the context of S. Wang et al., 2018.

Reviewer \#1:

In this manuscript, Zumaquero et al., analyse the role of IFNγ singling in human B cells. They found that this cytokine is necessary for the differentiation of naive B cells (BN: IgD+CD27-) into an intermediate developmental stage expressing T-bet (BDN:IgD-CD27-) that has the phenotype of an antibody-secreting cell precursor (pre-ASCs, IRF4+CD38-). They further show that IFNγ increases the differentiation of naive B cells to ASCs by promoting IL21 receptor expression and in this way, their responsiveness to IL-21. They provide compelling mechanistic clues to this phenomenon: IFNγ-induced T-bet expression in B cells would be epigenetically modifying IL21R gene and in this way, elevating the levels of IL-21R. Interestingly, authors found that these intermediate T-bet expressing pre-ASCs are phenotypically similar to auto-reactive B cells found in a subset of SLE patients (T-bet+IgD-CD27-) displaying elevated IFNγ levels in their blood. To provide physiological relevance to this phenomenon, authors generated mouse chimeras to show that T-bet expressing B cells are required for disease progression in a mouse model of SLE. Finally, authors conclude that the auto-reactive B cells found in SLE patients are not memory B cells as previously thought, but a pool of antigen-experienced pre-ASCs expressing intermediate levels of BLIMP and IRF4 that differentiate into ASCs following IL-21 exposure.

The data provided by the authors are very attractive and interesting. The authors not only uncover an intermediate differentiation stage of human B cells upon exposure to IFNγ but also demonstrate that auto-reactive B cells found in certain SLE patients have similar characteristics to this intermediate T-bet expressing B cell stage. Experiments are well performed and conclusions are supported by a vast amount of data. I have a positive view of this manuscript.

The only inquietude I have is whether this T-bet intermediate B cell differentiation stage would appear in vivo, for example, during immunization. Is IFNγ and T-bet required for ASCs generation after in vivo vaccination? Apart from that, their data is very solid, novel and the manuscript is a good fit for *eLife*.

Reviewer \#2:

Summary:

IFNγ signaling underscores disease progression in mouse models of SLE. The investigators set out to define whether its transcription factor, T-bet drives autoantibody formation in human SLE. They first confirm that T-bet promotes the generation of autoimmunity in a mouse model of TLR7-driven SLE and then move on to evaluate its significance in the human scenario. Capitalizing on their previous observation that T-bet is upregulated in CD11c^hi^ B cells in SLE patients, now further refined to the CD27/IgD negative (B~DN~) compartment negative for CXCR5, the investigators find that this phenotype is correlated with elevated IFNγ and IFNγ-driven inflammatory cytokines, substrates that also promote the generation of CD11c^hi^ B cells in mice. The investigators then induced a SLE-BDN-like phenotype through Th1 mediated IFNγ activation of health B cell donor population *in vitro*. This population showed similar transcriptional properties as that from SLE patients, and, relative to stimulation by Th2 cells, provided a progenitor population for rapid ASC development. This differentiation pathway was distilled *in vitro* as a two-step process involving initial priming by BCR crosslinking and IFNγ signaling followed by temporally delayed proliferative cues provided by to IL-21 and TLR ligand. Notably IFNγ and BCR signals induced formation of a T-bet^hi^ B~DN~ pre-ASC population from naïve B cells in which (and in contrast to that seen with conventional IL-2 priming) chromatin accessibility of the IL21R locus was altered, leading to upregulation of IL-21R expression. Finally, the investigators isolate this population from SLE patents and demonstrated that it was capably of IL21-dependent differentiation into ASC. Importantly they also note that T-bet^lo^ B~DN~ cells were also capable of differentiating in an IL21-independent manner, indicating that in humans the B~DN~ population remains phenotypically and functionally heterogeneous.

General comments:

This study was extremely well planned and executed. Through exhaustive functional studies on isolated human B cell subsets, the authors distill the signaling input and molecular basis needed for test-tube recapitulation of a pathway underscoring SLE in humans. This paper identifies and elucidates the central role T-bet plays in potential predisposition for this disorder in people and was cross-validated across multiple levels, starting with the mouse model, through pathway recapitulation with naïve human B cells in vitro, back through to the SLE phenotype in patents. I recommend publication, after addressing the points below.

1\) Figure 1. Representative flow plots should be included to validate the T-bet expression in the bone marrow chimeras.

2\) Figure 1H. IF the two SLE groups are merged into one do the cytokine differences remain significantly different from HD? The difference with the SLE patents suggests heterogeneity with the cohort. Is there anything that might explain this?

3\) Figure 2. Can the authors recapitulate the Be1 phenotype using cytokine manipulation alone? If so, what is the minimal cocktail that can deliver the phenotype?

4\) Figure 5I. Why does the -/- anti IgG group now give 11% ASC generation on day 6, whereas in Figure 5C it gave zero at this time point?

5\) Figure 9A,B vs Figure 9D. Figure 9A,B show that IL21R is has gone up by day 6 in Be.IFNγ and Be.g2. But Figure 9D shows that IL21 levels have gone down by day 6, relative to where they started. Can the authors explain this?

Reviewer \#3:

This is a lengthy and complex collection of experiments aimed at resolving the development, function and disease contribution of Tbet+ B cells in the autoimmune disease, SLE. Given this broad remit, it is not surprising that the experimental systems are varied and complex, ranging from mice, to human ex vivo cultures and to in vivo assessments in patients. It does make the report, however, quite difficult to follow and to determine whether each part actually contributes to the ultimate goal, and if in fact that goal is actually achieved. Equally there is an issue of novelty in that much of the information reported here is already available, requiring a significant degree of coherence in my opinion, to justify acceptance in its current form.

I think that rather than being such a coherent, linear progression from an hypothesis to a series of experiments to a conclusion, the work instead is a curious mixture of vignettes on a relatively unique in vitro B cell differentiation model, that is finally shoehorned onto the disease. I find that the final inferences -- and not wanting to be rude, but I don\'t think there are many irrefutable conclusions -- are very modest in terms of disease insight, even allowing for what\'s already published.

For a start, Figure 1A-C should be removed -- the results, while being supportive of existing data, have no bearing on the remainder of the study and it is not referenced after the description. The remainder of Figure 1 makes an established connection, that the frequency of Tbet-expressing, CD11c^hi^ B cells is increased in SLE patients and corresponds with the presence of IFNγ. Many of these data are published in Wang et al., 2017.

Figure 2 describes what may be the signature culture system of this laboratory -- a system that promotes antibody secreting cell formation preferentially in conditions that contain IFNγ, compared to those that contain IL4. This is in the presence of IL21 in both and CD40L, factors which many investigators have reported as potent inducers of ASC formation for human B cells in vitro on their own. This is a disconnect for me, in that it suggests that the in vitro system is distinct or unique and I therefore wonder about the applicability of the results outside the culture system. However, it does show induction of Tbet in B cells exposed to IFNγ, again confirming existing reports. And it shows that the non-ASC developed in the presence of IFNγ look like a B cell fraction in SLE patients, a disease overwhelmingly associated with IFNγ signalling. I assume this from healthy donor B cells although it is not stated.

Figure 3 further characterises the in vitro differentiation, again with B cells from what I assume is a healthy donor (unstated). It shows preferential ASC differentiation in the IFNγ conditions, still in the presence of IL21 and IL2, which again others (eg Tangye) have shown to be potent inducers of ASC formation in conditions lacking IFNγ, making this hard to reconcile. The data are somewhat difficult to interpret as most panels show what I think is the percent of cells within the division peak that are of the phenotype indicated on the y-axis. Thus, Figure 3F shows 60% of cells in division 7 of Be1 conditions to be ASC, etc., but the percentages of the total population in each division can\'t be determined. Curiously in this culture, Be1 conditions produce 20% ASC (sum of values in Figure 3C) while Be2 produces 1.4%, despite both being in IL21! This is also in comparison to the 12% ASC in Be2 cultures in Figure 2I. Is this a donor difference? It is also surprising to see Figure 3 no error bars on the measurements, yet the experiment appears to have been done multiple times.

Figure 4 is apparently to show the similarity of the B cells in culture with IFNγ lacking CD27 and IgD -- the B~DN~ cells -- as having a propensity to differentiate into ASC. This is shown by comparing the gene signature of the Be1 B~DN~ cells to various populations. My problem with this is that there may be several reasons why they correlate, such as proliferation versus no proliferation (e.g. Bn cells used as a comparator). Equally, I find the amount of IRF4 in the fractions difficult to interpret. If there are significant non-proliferating (division 0) B cells in the culture, they will not express much of any IRF4. Proliferating B cells will express more IRF4, as they have to in order to proliferate, and ASC will express the most. I don\'t find this intermediate amount of IRF4 compelling evidence that these are ASC precursors. Equally the culture is unconvincing. CD38 is not a unique marker of ASC (as shown here by the very low frequency of actual ASC in the culture -- 5/100 cells for IgG -- despite CD38+ being 41%) and we are not shown the ELISPOT results immediately after sorting to show the purity of the population.

Figure 5, Figure 6, Figure 7, Figure 8 and Figure 9 I found particularly confusing relative to the narrative of the work. They could be excised without any loss to the \'story\' as they represent a detailed examination of this culture system without much attempt to show the relevance of either the factors, the amounts or the order of addition and/or removal to the processes driving B cell differentiation in normal let alone SLE conditions. I simply don\'t get these figures at all, in addition to be very complex. One curious comment was that the Tbet-hi B~DN~ Be1 cells are responding to endogenous TLR ligands. That is pretty curious, and I wonder what evidence there is and what endogenous ligands they think are in action? I also find it very puzzling that the culture returns the result that IFNγ is a potent B cell mitogen or facilitator of B cell proliferation (Figure 8). This is, as far as I am aware, a unique finding.

Last within this group I take issue with the statement that the experiments in Figure 9 test in any way the hypothesis that \"IFNγ-induced Tbet might alter the epigenetic profile of the B cells\". The results do not support the subsequent conclusion that by \"promoting upregulation of Tbet, which modifies chromatin accessibility of the IL21R locus in the IFNγ stimulated B cells\". No. An association is shown but there is definitely no causation.

Figure 10 appears to be based on 1 patient and to show that disease activity (as measured by antibody titres) correlates with the appearance of Tbet^hi^ B~DN~ cells. Again, I am reasonably confident this has been reported, maybe with slightly different criteria, but same message. This figure is intended to tie the study together to show that the Tbet B~DN~ cells in SLE patients have the differentiation potential that has been described for B~DN~ cells derived in the in vitro cultures. They do, to an extent, but is this sufficient proof to say that the processes used in vitro to produce these cells in vitro are the processes that occurred in vivo to make the phenotypically similar cells? I think not. In part this is due to the what I think is the very poor efficiency of the culture system in which 10\^5 B~DN~ B cells were put in for stimulation but only 400 IgG ASC came out? (Figure 10K).

Overall this is a long, complicated and ultimately hard to follow report that I don\'t think supports the claimed conclusions.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"IFNγ induces epigenetic programming of human T-bet^hi^ B cells and promotesTLR7/8 and IL-21 induced differentiation\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Tadatsugu Taniguchi (Senior Editor), a Reviewing Editor, and three reviewers.

Thank you for your resubmission and the efforts to address the reviewers comments. Reviewers were satisfied on how you have addressed their comments, but at the same time they are concerned about the presentation of the manuscript. As you will see from their comments, there is a sense of a large amount of data but a lack of clarity in the overall message. At this point, we do not require from you new data to be added to the manuscript, but we would like to ask you to make an effort to streamline the text to make it clear and easy to follow, with main novel data in the main figures and the supporting material in supplementary. We are attaching reviewers comments of reviewer 3 so you can address the issues.

Reviewer \#1:

Authors addressed all my concerns. They generated a new figure showing that t-bet+ B cells appear following flu vaccination and they are phenotypically similar to the DN2 B cells found in SLE patients and B~DN~ cells generated in their ex vivo culture system. They should consider adding this figure as supplementary for the paper and shortening the main text. I support its publication in *eLife*.

Reviewer \#2:

The authors have made a strong and commendable effort to address the concerns I articulated in the first review. This version of the manuscript is a marked improvement, and for the reasons articulated in the first review feel this paper can now be published.

Reviewer \#3:

I note with some regret that virtually nothing I suggested has been acted on other than the very obvious corrections and improved scientific practice. I still find the paper overly long, overly complex, somewhat repetitive of existing information -- including from papers published by this group -- and also somewhat self-serving. By this last term I mean that having made (again) the observation that there are expanded Tbet+, activated B cells in SLE patients, it is now claimed in the discussion that the expansion of these cells in SLE is predicted by their discovery (Discussion section).

The manuscript remains very long (10 figures with 135 panels; 2 supplementary figures and 6 supplementary files; 85 references; 5 pages of discussion etc. plus a 114 page rebuttal with 8 figures of its own and 12 references), very complex and somewhat impenetrable. I note also that the other referees do not share any/many of my concerns, so I accept that these futile requests for clarity and brevity are probably more about me than anything else.

10.7554/eLife.41641.041

Author response

> As you might see from the reviews comments there has been some disagreement about the novelty of the work. Nevertheless, after discussion with the reviewers, we have decided to consider a revised version of the manuscript in which a considerable effort needs to be focused in incorporations their comments and most importantly streamline the main message of the manuscript. We have decided to copy all reviewers comments to assist you with this. In your revised manuscript it will be important to discuss the novelty of the work in in the context of S. Wang et al., 2018.
>
> Reviewer \#1:
>
> In this manuscript, Zumaquero et al., analyse the role of IFNγ singling in human B cells. They found that this cytokine is necessary for the differentiation of naive B cells (BN: IgD+CD27-) into an intermediate developmental stage expressing T-bet (BDN:IgD-CD27-) that has the phenotype of an antibody-secreting cell precursor (pre-ASCs, IRF4+CD38-). They further show that IFNγ increases the differentiation of naive B cells to ASCs by promoting IL21 receptor expression and in this way, their responsiveness to IL-21. They provide compelling mechanistic clues to this phenomenon: IFNγ-induced T-bet expression in B cells would be epigenetically modifying IL21R gene and in this way, elevating the levels of IL-21R. Interestingly, authors found that these intermediate T-bet expressing pre-ASCs are phenotypically similar to auto-reactive B cells found in a subset of SLE patients (T-bet+IgD-CD27-) displaying elevated IFNγ levels in their blood. To provide physiological relevance to this phenomenon, authors generated mouse chimeras to show that T-bet expressing B cells are required for disease progression in a mouse model of SLE. Finally, authors conclude that the auto-reactive B cells found in SLE patients are not memory B cells as previously thought, but a pool of antigen-experienced pre-ASCs expressing intermediate levels of BLIMP and IRF4 that differentiate into ASCs following IL-21 exposure.
>
> The data provided by the authors are very attractive and interesting. The authors not only uncover an intermediate differentiation stage of human B cells upon exposure to IFNγ but also demonstrate that auto-reactive B cells found in certain SLE patients have similar characteristics to this intermediate T-bet expressing B cell stage. Experiments are well performed and conclusions are supported by a vast amount of data. I have a positive view of this manuscript.

We thank reviewer 1 for their positive view of our manuscript and are happy to see that the reviewer believes that our manuscript is appropriate for publication in *eLife*.

> The only inquietude I have is whether this T-bet intermediate B cell differentiation stage would appear in vivo, for example, during immunization. Is IFNγ and T-bet required for ASCs generation after in vivo vaccination? Apart from that, their data is very solid, novel and the manuscript is a good fit for eLife.

We originally planned to include this data in the manuscript but we removed it from the submitted version because the paper was already too long and too dense (one of the criticisms of reviewer 3). We find circulating influenza-specific (hemagglutinin (HA) binding) switched memory (B~SW~, CD27^+^IgD^neg^) and double negative (B~DN~ IgD^neg^CD27^neg^) B cells following influenza vaccination. Many of these vaccine HA-specific B cells express high levels of T-bet ([Author response image 1A-B](#respfig1){ref-type="fig"}) and the frequency of these cells increases between days 7-21 post-vaccination ([Author response image 1C](#respfig1){ref-type="fig"}). Thus, these cells are not only induced in the setting of pathogenic disease (i.e. SLE) but are also detected during normal immune responses. Interestingly the T-bet^hi^ HA-specific B cells, like the T-bet^hi^ DN2 population found in SLE patients or our in vitro induced T-bet^hi^ B~DN~ cells, also express CD11c and FcRL5 and have downregulated CXCR5 ([Author response image 1D](#respfig1){ref-type="fig"}). Moreover, the influenza HA-specific T-bet^hi^ B~DN~ subset is transcriptionally related to the Tbet^hi^ DN2 cells from SLE patients and express intermediate levels of Blimp1 and IRF-4 (data not shown). In the revised version of this *eLife* manuscript, we mention these results as data not shown.

![Influenza vaccination induces formation of hemagglutinin (HA)-specific T-bethi B cells.\
(**a-c**) Identification and enumeration of HA-specific T-bethi lgDnegCD27+ (B~SW~) cells (**a**) and HA-specific T-bethi lgDnegcD27neg (B~DN~) cells (**b**) between 0-28 days following vaccination with 2015-16 Fluzone. Representative flow plots (**a-b**) from a single individual and quantitation (**c**) of B cell subsets in 19 vaccinated healthy donors. Data in (**c**) reported as the frequency of T-bethi HA+ B cells within each subset. Individual subjects are represented by a symbol. Horizontal lines represent the median value for each group. (**d**) Flow cytometric analysis of HA-specific T-bethi B cells reveal that the cells are phenotypically similar to SLE DN2 cells and are CD11c+FcRL5+CXCR5neg. Statistical analysis in (**c**) was performed using a non-parametric Mann-Whitney test. P values.](elife-41641-resp-fig1){#respfig1}

> Reviewer \#2:
>
> Summary:
>
> IFNγ signaling underscores disease progression in mouse models of SLE. The investigators set out to define whether its transcription factor, T-bet drives autoantibody formation in human SLE. They first confirm that T-bet promotes the generation of autoimmunity in a mouse model of TLR7-driven SLE and then move on to evaluate its significance in the human scenario. Capitalizing on their previous observation that T-bet is upregulated in CD11c^hi^ B cells in SLE patients, now further refined to the CD27/IgD negative (B~DN~) compartment negative for CXCR5, the investigators find that this phenotype is correlated with elevated IFNγ and IFNγ-driven inflammatory cytokines, substrates that also promote the generation of CD11c^hi^ B cells in mice. The investigators then induced a SLE-BDN-like phenotype through Th1 mediated IFNγ activation of health B cell donor population in vitro. This population showed similar transcriptional properties as that from SLE patients, and, relative to stimulation by Th2 cells, provided a progenitor population for rapid ASC development. This differentiation pathway was distilled in vitro as a two-step process involving initial priming by BCR crosslinking and IFNγ signaling followed by temporally delayed proliferative cues provided by to IL-21 and TLR ligand. Notably IFNγ and BCR signals induced formation of a T-bet^hi^ B~DN~ pre-ASC population from naïve B cells in which (and in contrast to that seen with conventional IL-2 priming) chromatin accessibility of the IL21R locus was altered, leading to upregulation of IL-21R expression. Finally, the investigators isolate this population from SLE patents and demonstrated that it was capably of IL21-dependent differentiation into ASC. Importantly they also note that T-bet^lo^ B~DN~ cells were also capable of differentiating in an IL21-independent manner, indicating that in humans the B~DN~ population remains phenotypically and functionally heterogeneous.
>
> General comments:
>
> This study was extremely well planned and executed. Through exhaustive functional studies on isolated human B cell subsets, the authors distill the signaling input and molecular basis needed for test-tube recapitulation of a pathway underscoring SLE in humans. This paper identifies and elucidates the central role T-bet plays in potential predisposition for this disorder in people and was cross-validated across multiple levels, starting with the mouse model, through pathway recapitulation with naïve human B cells in vitro, back through to the SLE phenotype in patents. I recommend publication, after addressing the points below.

We thank reviewer 2 for their positive comments and we are pleased that the reviewer recommends publication in *eLife*.

> 1\) Figure 1. Representative flow plots should be included to validate the T-bet expression in the bone marrow chimeras.

This data is provided (see and Figure 1---figure supplement 1 in revised manuscript).

> 2\) Figure 1H. IF the two SLE groups are merged into one do the cytokine differences remain significantly different from HD? The difference with the SLE patents suggests heterogeneity with the cohort. Is there anything that might explain this?

Yes, systemic levels of IFNγ, CXCL10 and TNFα are heterogenous within our SLE cohort (Figure 1K-L). However, when all the SLE samples are combined for the analysis, we still observe significant differences in systemic cytokine levels between the SLE patients and healthy donors (HD) ([Author response image 2A-C](#respfig2){ref-type="fig"}). Moreover, the positive correlation between inflammatory cytokine levels and the frequencies of circulating T-bet^hi^ B cells is still evident when all SLE patient samples are combined for the analysis ([Author response image 2D-F](#respfig2){ref-type="fig"}). Interestingly, we find that the Caucasian SLE patients in our cohort (shown in green circles in [Author response image 2](#respfig2){ref-type="fig"}) uniformly express low levels of these inflammatory cytokines and have fewer circulating T-bet^hi^ B cells. By contrast, the individuals with the highest frequencies of T-bet^hi^ B cells and the highest levels of systemic inflammatory cytokines are African Americans (shown in red circles in [Author response image 2](#respfig2){ref-type="fig"}). This is consistent with data from two recent publications demonstrating that the T-bet^hi^ B~DN~ subset (DN2 cells) is more prominent in a subset of African American SLE patients (Jenks et al., 2018; Wang et al., 2018). While this may be due to genetic and/or environmental differences between these two patient populations, we do know that the frequency of circulating DN2 cells correlates with disease severity (as measured by SLEDAI score, (Jenks et al., 2018)) and that disease severity is increased in a subset of African American women. Therefore, we suspect that those individuals who present with the highest levels of IFNγ-driven cytokines and T-bet^hi^ B cells are those with more active, less well-controlled severe disease (who are often AA in our cohort of patients). This point is now discussed in the revised manuscript.

![Positive correlation between high systemic levels Of inflammatory cytokines and frequency Of circu- lating T-bethi B cells in SLE patients.\
(**a-c**) Plasma concen- tration of IFN7 (**a**) CXCLIO (**b**) and TNFa (**c**) in 5 healthy donors (blue symbols) and 25 SLE patients (red and green symbols). (**d-f**). Correlation between IFN7 (**d**), CXCLIO (**e**) and TNFa (**f**) plasma cytokine levels and frequency of T-bethi B cells in SLE patient peripheral blood. Red and green symbols identify 21 African Americans and 4 Caucasian patients respectively. Statistical analyses were performed using non- parametric Mann-Whitney test (**a-c**) and Spearman Correla- tion test (**d-f**).](elife-41641-resp-fig2){#respfig2}

> 3\) Figure 2. Can the authors recapitulate the Be1 phenotype using cytokine manipulation alone? If so, what is the minimal cocktail that can deliver the phenotype?

We show that co-culture of naïve B cells with Th1 cells + IL-21 and IL-2 is sufficient to generate ASCs and a population of pre-ASCs (IgD^neg^CD27^neg^ Be1~DN~ cells) that are phenotypically, functionally and molecularly similar to the T-bet^hi^ DN2 cells that are expanded in a subset of SLE patients (i.e. T-bet^hi^ IRF4^int^, CD11c^+^FcRL5^+^). In revised Figure 5D-E, we show that stimulation of naïve B cells (from HD and SLE patients) with anti-Ig + TLR 7/8 ligand in the presence of IFNγ, IL-2, IL-21 and BAFF is sufficient to induce the formation of effector DN2-like B cells that are CD27^neg^IgD^neg^, T-bet^hi^IRF4^int^, CD11c^+^FcRL5^+^CD21^neg^ and have begun downregulating CXCR5. In Figure 5, Figure 6 and Figure 7 of the manuscript, we defined the minimal signaling elements required for the formation of the DN2-like pre-ASCs and subsequent ASCs. In this analysis, we defined the pre-ASC population as IgD^neg^CD27^neg^T-bet^hi^IRF4^int^. For brevity, we didn't show all of the data but we did look at how each stimulus influences expression of these markers and others (i.e. CD11c, CXCR5, CD21 and FcRL5) that are used to identify T-bet^hi^ DN2 cells. As we presented in the paper, only IFNγ signaling induced the Tbet^hi^IRF4^int^ phenotype (see Figure 6 and Figure 7). However, IFNγ signals are not obligate for CD11c and FcRL5 upregulation or downregulation of CD21 and CXCR5. Instead, and consistent with prior publications (Ettinger et al., 2005; Kuchen et al., 2007), we found that down-regulation of IgD can be induced by other cytokines including IL-21 and IL-2 and IFNγ. Moreover, like others have reported (Masilamani et al., 2003; Naradikian et al., 2016; Wang et al., 2018), BCR stimulation promoted downregulation of CXCR5 and CD21, while IL-21 facilitated upregulation of CD11c and FcRL5. TLR7/8 and IL-2 signals, while important for cell proliferation/recovery, were dispensable for acquisition of the Tbet^hi^ DN2 phenotype. Therefore, our data suggest that a minimal stimulation cocktail consisting of BCR ligand + TLR7/8 + IFNγ + IL-2 + IL-21 can induce recoverable numbers of pre-ASCs that are very similar phenotypically to the T-bet^hi^ DN2 cells found in SLE patients. This stimulation cocktail was used for the experiments shown in Figure 8, Figure 9 and Figure 10 of the manuscript.

> 4\) Figure 5I. Why does the -/- anti IgG group now give 11% ASC generation on day 6, whereas in Figure 5C it gave zero at this time point?

Figure 5C from the first version of the manuscript (now revised Figure 5F) examined B cells that were continuously stimulated for 6 days in the presence of anti-Ig (+/+ conditions) while the Figure 5I panel (now revised Figure 5M) with 11% ASCs examined the cultures that were activated for 6 days in the absence of anti-Ig (-/- conditions). Therefore, these two panels are not examining the same stimulation conditions. We found that anti-Ig stimulation between days 3-6 of the cultures (+/+ and -/+ conditions) impaired ASC formation in our in vitro cultures. By contrast, B cells that were either transiently activated with anti-Ig (+/-) or not stimulated with anti-Ig (-/-) did differentiate into ASCs. In the experiment shown in revised Figure 5G (+/+ conditions) we detected no ASCs in the cultures on day 6. In revised Figure 5m, we find lower frequencies of ASCs in the +/+ cultures (3.2%) and in the -/+ cultures (1.36%) compared to the +/- cultures (17.4%) and -/- cultures (11%).

> 5\) Figure 9A,B vs Figure 9D. Figure 9A,B show that IL21R is has gone up by day 6 in Be.IFNγ and Be.g2. But Figure 9D shows that IL21 levels have gone down by day 6, relative to where they started. Can the authors explain this?

The original Figure 9B-C (now revised Figure 9E-F) examined IL21R expression on Day 3 (revised Figure 9E) and Day 6 (revised Figure 9F) while the original Figure 9D (now revised Figure 9G) examined IL-21R expression on day 6 of the cultures. As the reviewer noted, the expression of IL21R increases between days 3 and 6 on the bulk (total) B lineage cells in the cultures (revised Figure 9E vs revised Figure 9F). The reviewer is also correct that IL21R expression does drop on a subset of the B lineage cells in the cultures on day 6 (most easily seen in revised Figure 9G but also evident in revised Figure 9F). The B cells expressing the lowest levels of IL21R on day 6 are the B cells that have undergone the most rounds of division (as measure by CTV dilution, see revised Figure 9G). These extensively divided B cells that express lower levels of IL21R are the CD27^hi^CD38^hi^ ASCs that are found in the day 6 cultures. This is evident when the day 6 cells are subdivided into ASCs and non-ASCs ([Author response image 3](#respfig3){ref-type="fig"}). Therefore, our data show that IFNγ induces upregulation of IL21R in the Be.IFNγ and Be.g2 cells and suggest that as these cells differentiate into ASCs, IL21R expression levels begin to decline.

![IL21R expression levels decline as B cells differentiate into ASCs.\
BN cells were activated for 3 days with anti-lg, R848, IFNY and IL-2, then washed and cultured for an additional 3 days with IL-21 and R848 (Be.Y2 cells). ASCs (CD27hiCD38hi and non-ASCs were identified in the Be.Y2 cultures (**a**) and IL21R expression levels were evaluated in each subset and are reported as histograms (**b**).](elife-41641-resp-fig3){#respfig3}

> Reviewer \#3:
>
> This is a lengthy and complex collection of experiments aimed at resolving the development, function and disease contribution of Tbet+ B cells in the autoimmune disease, SLE. Given this broad remit, it is not surprising that the experimental systems are varied and complex, ranging from mice, to human ex vivo cultures and to in vivo assessments in patients. It does make the report, however, quite difficult to follow and to determine whether each part actually contributes to the ultimate goal, and if in fact that goal is actually achieved. Equally there is an issue of novelty in that much of the information reported here is already available, requiring a significant degree of coherence in my opinion, to justify acceptance in its current form.
>
> I think that rather than being such a coherent, linear progression from an hypothesis to a series of experiments to a conclusion, the work instead is a curious mixture of vignettes on a relatively unique in vitro B cell differentiation model, that is finally shoehorned onto the disease. I find that the final inferences -- and not wanting to be rude, but I don\'t think there are many irrefutable conclusions -- are very modest in terms of disease insight, even allowing for what\'s already published.

It is true that the manuscript is densely packed with data from multiple types of in vitro and in vivo model systems and that it could potentially be condensed. However, we believe that our data do as reviewer 2 summarized "distill the signaling input and molecular basis needed for test-tube recapitulation of a pathway underscoring SLE in humans. This paper identifies and elucidates the central role T-bet plays in potential predisposition for this disorder in people and was cross-validated across multiple levels, starting with the mouse model, through pathway recapitulation with naïve human B cells in vitro, back through to the SLE phenotype in patients." Moreover, we think that our in vitro model system provides a platform for testing the potential origins of the T-bet^hi^ pre-ASC B cell subset (DN2 cells) -- a subset that is of great interest in a variety of disease settings. In addition, we think that our in vitro model system may also be very useful for directly testing which pathways are amenable to targeting the development of this subset of pathogenic B cells in humans. Finally, we think that the data presented here are novel in that the data describe the stimulation conditions that are needed (albeit in vitro) to induce the formation of human T-bet^hi^ pre-ASCs and demonstrate that these pre-ASCs can differentiate into ASCs when appropriately stimulated. Most importantly, our original data plus new data provided in revised Figure 9 and Figure 10, are the first to show that IFNγ signals specifically synergize with TLR7/8 and IL-2 to drive the epigenetic remodeling of the BCR activated B cells and increase chromatin accessibility within the IL21R and PRDM1 loci as well increasing accessibility around BLIMP1 and IRF4 binding sites within the genome.

> For a start, Figure 1A-C should be removed -- the results, while being supportive of existing data, have no bearing on the remainder of the study and it is not referenced after the description.

The existing data examining T-bet expressing B cells in SLE mouse models includes three publications that arrive at diametrically opposing conclusions. Two papers conclude that T-bet expressing B cells play no role in autoantibody-mediated disease (Du et al., 2019; Jackson et al., 2016) while one study indicates that Tbet expressing B cells are necessary for the development of autoantibodies in their model of SLE (Rubtsova et al., 2017). Using a completely distinct model of SLE (Yaa.Fcgr2b^-/-^) that is driven by gene duplication and over-expression of the TLR7 gene, we demonstrate a clear role for T-bet expressing B cells driving the formation of autoantibodies, kidney damage and mortality. We believe that these data do have bearing on the rest of the manuscript as our data show that IFNγ, which is obligate for expression of T-bet in human B cells activated with TLR ligands, antigen and IL-21, synergizes with TLR7/8 and IL21 to promote expansion and differentiation of human B cells. In the revised manuscript we summarize the mouse data in one sentence, move the data to Figure 1---figure supplement 1 and refer back to the mouse data in the Discussion section.

> The remainder of Figure 1 makes an established connection, that the frequency of Tbet-expressing, CD11c^hi^ B cells is increased in SLE patients and corresponds with the presence of IFNγ. Many of these data are published in Wang et al., 2017.

It is true that there are similarities between the data in the original Figure 1 and the data published by Wang et al., 2018et al.. However, the experiments published by Wang and Jenks used surface markers (like CD11c, FcRL5, CD21 or CXCR5) to subdivide the B cells in SLE patients while we subdivide the B cells using the transcription factor T-bet. While this may seem like a largely semantic point, our paper is focused on how IFNγ drives ASC development and T-bet, unlike any of the other markers analyzed in the other papers, is induced in an IFNγ-dependent manner in human B cells and serves as a biomarker for B cells that have undergone IFNγ-dependent programming. More importantly, Figure 1 also includes novel data that is not found in the Wang paper (or published elsewhere) showing a direct and significant correlation between the levels of systemic inflammatory IFNγ and IFNγ-induced cytokines and the frequency of the T-bet^hi^ DN2 cells (revised Figure 1K-L). We think that the data in Figure 1 provide context and justification for rest.

> Figure 2 describes what may be the signature culture system of this laboratory -- a system that promotes antibody secreting cell formation preferentially in conditions that contain IFNγ, compared to those that contain IL4. This is in the presence of IL21 in both and CD40L, factors which many investigators have reported as potent inducers of ASC formation for human B cells in vitro on their own. This is a disconnect for me, in that it suggests that the in vitro system is distinct or unique and I therefore wonder about the applicability of the results outside the culture system.

Although the reviewer is correct that in vitro systems to measure human B cell differentiation have been developed and that antigen and signals provided by T cells, including IL-21 and CD40L, can promote ASC formation, most of those experiments were performed with either total CD19^+^ B cells (which includes many memory B cells) or purified memory B cells. Remarkably few studies have examined culture conditions that promote naïve B cells to differentiate into ASCs and in general, few ASCs are detected in these cultures (on the order of 5%, see for e.g. (Berglund et al., 2013; Deenick et al., 2013; Ettinger et al., 2005)). Our novel finding in this paper is that IFNγ greatly augments the differentiation of naïve human B cells. In as few as 4-5 days (cultures with Th1 cells + IL-21) or 5-6 days (defined activation cocktail that includes only IFNγ, IL21, Anti-Ig and R848), we can recover large numbers of ASCs that are simply not found at these timepoints if IFNγ is not included in the cultures.

> However, it does show induction of Tbet in B cells exposed to IFNγ, again confirming existing reports.

Yes, it is well known that IFNγ can induce expression of T-bet in mouse and human B cells. However, it is also reported that IL-21 and TLR ligands are potent inducers of T-bet in B cells (Naradikian et al., 2016; Wang et al., 2018). We show in this manuscript that neither IL-21 nor the TLR ligand R848 is sufficient to induce the formation of the T-bet expressing pre-ASC subset described here and that Tbet upregulation and the development of the T-bet^hi^ B~DN~ population (DN2-like cells) requires IFNγ. These data are novel.

> And it shows that the non-ASC developed in the presence of IFNγ look like a B cell fraction in SLE patients, a disease overwhelmingly associated with IFNγ signalling.

It is true that a [subset]{.ul} of human SLE patients exhibit an IFNγ-induced gene signature, however no one, to our knowledge, has defined a set of in vitro stimulation conditions that is necessary and sufficient to induce the formation of a T-bet expressing pre-ASC population that mirrors many of the phenotypic, molecular and functional properties of the pre-ASC DN2 population that is expanded in a subset of SLE patients and is associated with disease severity (Jenks et al., 2018; Wang et al., 2018).

> I assume this from healthy donor B cells although it is not stated.

The data in the original and revised Figure 2 is derived from naïve B cells isolated from health donors (HD). We now explicitly state this in the figure legend and have clarified which B cells were used in each experiment throughout the manuscript.

> Figure 3 further characterises the in vitro differentiation, again with B cells from what I assume is a healthy donor (unstated).

Yes, and we modified the figure legends to make this point more clearly.

> It shows preferential ASC differentiation in the IFNγ conditions, still in the presence of IL21 and IL2, which again others (eg Tangye) have shown to be potent inducers of ASC formation in conditions lacking IFNγ, making this hard to reconcile.

Yes, it is true the Tangye's group (and others) demonstrated that ASCs are formed when naïve B cells are activated in the presence of IL-21 and IL-2. Indeed, Tangye's paper (Berglund et al., 2013) shows that the frequency of ASCs in cultures containing naïve B cells activated with CD40L, IL21, and IL2 is 4.6%. Similarly, in 5 independent experiments (rev. Figure 3F-I and Figure 3---figure supplement 2D-F) we enumerated an average of 3.9% ASCs (range 0.2-10%) in the Be2 cultures. What is novel in our paper is that we enumerated an average of 24.1% ASCs (range 6.7-57%) in the Be1 cultures. More importantly, in 15 paired Be1 and Be2 co-cultures, we observed more ASCs in the Be1 cultures relative to the Be2 cultures (revised Figure 3B). Therefore, our contribution to the field is that we show that IFNγ-producing T cells greatly augment ASC development from naïve human B cells. We make this point more clearly in the discussion of the revised manuscript.

> The data are somewhat difficult to interpret as most panels show what I think is the percent of cells within the division peak that are of the phenotype indicated on the y-axis. Thus 3f shows 60% of cells in division 7 of Be1 conditions to be ASC, etc, but the percentages of the total population in each division can\'t be determined.

The reviewer is correct, that the original Figure 3F showed that \~60% of the cells that have divided 7+ times in the Be1 cultures are ASCs while less than 2% of the cells in division 7+ are ASCs in the Be2 cultures. This is despite the fact that the proliferative response of the B cells in the two cultures is basically identical (original Figure 2F). In the revised manuscript, we provide data from 5 experiments using independent paired Be1 and Be2 co-cultures (revised Figure 3E-J, revised Figure 3---figure supplement 1A-I and [Author response image 4](#respfig4){ref-type="fig"}). Each of the 5 experiments show that the frequency of ASCs (whether defined by CD19^lo^CD38^hi^CD27^hi^, CD19^lo^CD38^hi^IRF4^hi^, or CD19^lo^CD38^hi^) is increased in the day 5-6 Be1 cultures compared to the day 5-6 Be2 cultures. The data show that cell division within each paired co-culture is very similar, suggesting that the increased ASC formation in the Be1 cultures is not due to increased proliferation. Finally, when we examine the cells that divided 6+ times in both co-cultures, we always find that a higher proportion of those cells are ASCs in the Be1 cultures compared to Be2 cultures. Collectively, these results indicate that ASC formation is augmented in the Be1 co-cultures.

![ASC formation is augmented and accelerated in Bel co-cultures.\
(**a-o**) Proliferation and ASC formation were measured in 5 independent (Examples 1-5) day 5-6 paired Bel and 3e2 Go-cultures that contained purified CTV-IabeIed BN cells and allogenic Thl or Th2 cells plus IL-2 and IL-21 , proliferation analysis (**a, d, g, j, m**) Of B lineage cells in the day 5-6 co-cultures showing the frequency Of CD19•n0 cells in each cell division. Analysis Of ASC formation in day 5-6 Go-cultures (**b, e, h, k, n**) showing the frequency of ASCs within the CD19•\'1a gated cells. ASCs defined as CD1910CD3BhilRF4hi (**b, k**), CD19ZCD3BhiCD27• (**e**) or CD1910CD38hi (**h, n**). proliferation analysis (**c, f, i, l, o**) the ASCs and non-ASCs in each cell division. Data are shown as the proportion of cells within each division that are ASCs.](elife-41641-resp-fig4){#respfig4}

> Curiously in this culture, Be1 conditions produce 20% ASC (sum of values in 3c) while Be2 produces 1.4%, despite both being in IL21!

That's actually the major point we want to make -- we find an average of 6 times more ASCs in the paired Be1 co-cultures relative to the Be2 cultures. This is despite the fact that both cultures contain naïve B cells (from the one donor), exogenous IL-21 + IL-2, and alloeffector T cells (that were generated from another donor). Moreover, the increase in ASCs in the Be1 cocultures is not due to changes in the proliferative potential of the B cells as the proliferative rate of the cells in the paired co-cultures is identical. Again, our data does not demonstrate that ASCs formation is absolutely reliant on IFNγ but we show that ASC formation is significantly more robust when IFNγ is included. We now make this point more clearly in the results and discussion.

> This is also in comparison to the 12% ASC in Be2 cultures in Figure 2i. Is this a donor difference?

There is donor to donor variation in the paired Be1 and Be2 co-cultures (compare [Author response image 4A](#respfig4){ref-type="fig"} (Example 1) to [Author response image 4D](#respfig4){ref-type="fig"} (Example 2)). In Example 2 co-cultures, only 10% of the Be1 and Be2 cells have divided 6+ times by day 6. By contrast, in Example 1 co-cultues, \>60% of the Be1 and Be2 cells have divided 6+ times. However, in each paired co-culture the proliferative rates of the Be1 and Be2 cells are directly comparable. Despite this, we always find more ASCs in the Be1 cultures compared to the Be2 cultures.

> It is also surprising to see Figure 3 no error bars on the measurements, yet the experiment appears to have been done multiple times.

We did not include error bars on the CTV measurements because there is donor to donor variation in the allo-reactive cultures that do affect the rate of proliferation within the co-cultures (see [Author response image 4A](#respfig4){ref-type="fig"} (Example 1) and [Author response image 4D](#respfig4){ref-type="fig"} (Example 2)). This donor to donor variation in our co-cultures makes it impossible to combine data sets. To demonstrate to the reviewer that the data presented in the manuscript are representative of multiple experiments we provide 5 independent paired co-culture experiments (see revised Figure 3 and new Figure 3---figure supplement 1). In each of the 5 examples, the proliferative responses of the B cells in the Be1 and Be2 co-cultures are very similar. However, the frequency of ASCs is always higher in the Be1 co-cultures, regardless whether we define the ASCs as CD38^hi^CD19^lo^ or as CD19^lo^CD38^hi^IRF4^hi^ or CD19^lo^CD27^hi^CD38^hi^ (see [Author response image 4](#respfig4){ref-type="fig"}). Thus, we can confidently conclude that ASC formation is always augmented when B cells are activated in the presence of Th1 cells and that this increase is not due to an inability of the Be2 cells to divide.

> Figure 4 is apparently to show the similarity of the B cells in culture with IFNγ lacking CD27 and IgD -- the B~DN~ cells -- as having a propensity to differentiate into ASC. This is shown by comparing the gene signature of the Be1 B~DN~ cells to various populations. My problem with this is that there may be several reasons why they correlate, such as proliferation versus no proliferation (eg Bn cells used as a comparator).

In each GSEA we begin with collated lists of genes that are reported by others to be significantly upregulated in ASCs when the ASCs are compared to naïve B cells (revised Figure 4G), or to switched memory B cells (revised Figure 4I) or total B cells (revised Figure 4H). We then use GSEA to determine whether expression of these "ASC upregulated genes" are more highly expressed in either the Be1 B~DN~ cells or Be2 B~DN~ cells. In all 3 analyses, we find that the ASC signature genes are significantly enriched in the Be1 B~DN~ cells compared to the Be2 B~DN~ cells. We do not think that the enriched ASC gene signature in the Be1 B~DN~ cells is due to changes in the proliferative potential of Be1 and Be2 cells as these cells divide equivalently (see for example, [Author response image 4](#respfig4){ref-type="fig"}). Instead, we believe that the GSEA data suggests that more genes that are associated with the ASC program are upregulated in the Be1 B~DN~ cells compared to the Be2 B~DN~ cells. This is entirely consistent with our data showing that ASC formation is augmented in the Be1 co-cultures.

> Equally, I find the amount of IRF4 in the fractions difficult to interpret. If there are significant non-proliferating (division 0) B cells in the culture, they will not express much of any IRF4. Proliferating B cells will express more IRF4, as they have to in order to proliferate, and ASC will express the most. I don\'t find this intermediate amount of IRF4 compelling evidence that these are ASC precursors.

We agree with the reviewer that IRF4 expression levels can reflect B cell activation, proliferation and differentiation. Naïve B cells that haven't proliferated express very little IRF4, while B cells that have proliferated multiple times and differentiated into ASCs do express the highest levels of IRF4. To confirm this point, we added a new experiment (revised Figure 4M) where we examined cell division within the T-bet and IRF4 expressing cells present in the Be1 co-cultures. IRF4^neg^T-bet^neg^ cells (popA in Figure 4M) are undivided. These cells (which are IgD^+^) include the remaining naïve B cells. We can also identify a population of cells that express high levels of IRF4 and low levels of T-bet (popD in Figure 4M). These cells (which are CD38^hi^CD27^hi^ ASCs) have fully diluted the CTV indicating that the cells divided 6+ times. Finally, we defined 2 populations of cells that upregulate T-bet and express low to intermediate levels of IRF4 T-bet^hi^IRF4^lo/int^ (popB in Figure 4M) and T-bet^hi^IRF4^int/hi^ (popC in Figure 4M). These cells have divided multiple times, with the T-bet^hi^IRF4^lo/int^ (popB) cells having proliferated less times on average than the Tbet^hi^IRF4^int/hi^ (popC). Thus, it is not unreasonable to conclude that the cells in the culture that have differentiated into ASCs must pass through an intermediate stage where they first upregulate T-bet and then gradually upregulate IRF4. Consistent with this conclusion, GSEA revealed that genes that are directly induced by IRF4 in ASCs (relative to total B cells) are enriched in the T-bet^hi^IRF4^int^ Be1 B~DN~ cells (revised Figure 4J). Therefore, we conclude from these data that the T-bet^hi^IRF4^int^ population of B~DN~ cells found in the Be1 co-cultures are an intermediate population that are not ASCs but exhibit transcriptional programming consistent with a pre-ASC population.

> Equally the culture is unconvincing. CD38 is not a unique marker of ASC (as shown here by the very low frequency of actual ASC in the culture -- 5/100 cells for IgG -- despite CD38+ being 41%) and we are not shown the ELISPOT results immediately after sorting to show the purity of the population.

We addressed this concern with new data in revised Figure 4N-O. Briefly, we sorted the IgD^neg^CD27^neg^ B~DN~ cells from donor paired Be1 and Be2 co-cultures, labeled the cells with CTV and then put them in culture for 18 hours. Approximately 47% of the IgD^neg^CD27^neg^ sorted Be1 B~DN~ cells and 65% of the sorted IgD^neg^CD27^neg^ Be2 B~DN~ cells divided at least 1x within 18 hours (Figure 4A). No CD27^hi^CD38^hi^ ASCs were detected in the undivided B~DN~ subset, regardless of whether these cells were sorted from the Be1 or Be2 co-cultures (Figure 4A). Interestingly, approximately half (47.2%) of the actively proliferating Be1 B~DN~ cells differentiated into CD27^hi^CD38^hi^ ASCs within 24 hours (Figure 4A). By contrast, only 12.7% of the actively proliferating sorted Be2 B~DN~ cells differentiated into ASCs during that same timeframe. These data therefore indicate that approximately 1 in every 5 sorted Be1 B~DN~ cells differentiated into ASCs in 18 hours while only 1 in every 12 sorted Be2 B~DN~ cells differentiated into ASCs in the same timeperiod. In three independent experiments (Figure 4B), we observed an average 3.5 fold increase in ASC precursors in the sorted Be1 B~DN~ cells compared to Be2 B~DN~ cells. Thus, sorted B~DN~ cells from both Be1 and Be2 cultures are activated and dividing and a proportion of these cells can differentiate into ASCs within 1 cell division in less than 1 day. However, B~DN~ cells from the Be1 cultures generate \~3-4x more ASCs that the B~DN~ cells from the Be2 cultures in the same timeframe. Collectively, these data support the conclusion that the B~DN~ cells isolated from both Be1 and Be2 co-cultures are not ASCs but that this population includes pre-ASCs that can differentiate *rapidly* into ASCs after dividing one additional time. In addition, the data support the conclusion that the Be1 B~DN~ pre-ASC population supports significantly augmented and/or accelerated ASC formation relative to the Be2 B~DN~ pre-ASC population.

> Figure 5, Figure 6, Figure 7, Figure 8 and Figure 9 I found particularly confusing relative to the narrative of the work. They could be excised without any loss to the \'story\' as they represent a detailed examination of this culture system without much attempt to show the relevance of either the factors, the amounts or the order of addition and/or removal to the processes driving B cell differentiation in normal let alone SLE conditions.

The purpose of these figures is to identify the minimal signals that give rise to the T-bet^hi^ B~DN~ cells that we identified as pre-ASCs in our Be1/Th1 co-cultures. We used our RNA-seq data to identify the signaling pathways that are activated in the pre-ASCs and then replaced the T cells in the cultures with defined stimuli to see if we could recapitulate the development of the pre-ASC population. The data are complicated but we define a set of minimal signals (transient BCR ligation, IFNγ, TLR7/8, IL-2 and IL-21) that induce the development of the T-bet^hi^ DN2-like population in vitro. We show that B cells activated with antigen (BCR ligation) and TLR7/8 ligands in the presence of IFNγ form a T-bet^hi^ pre-ASC population that is phenotypically and molecularly similar to the T-bet^hi^ DN2 cells that are found in a subset of SLE patients and to the Be1 B~DN~ cells that we generated by co-culturing naïve B cells with Th1 cells + IL21 + IL-2. In new data (revised Figure 8 and Figure 9), we show that IFNγ augments ASC development by synergizing with TLR and IL-2 signals by poising the cells to become responsive to IL-21. We also provide new data (revised Figure 10) to show that IFNγ, particularly when combined with IL-2, globally impacts chromatin accessibility in the day 3 T-bet^hi^IRF4^int^ B~DN~ population that has not yet been exposed to IL-21. In addition, we observed significant increased chromatin accessibility surrounding BLIMP1 and IRF4 binding motifs in the B cells activate in the presence of IFNγ + IL-2, suggesting ongoing chromatin remodeling around regulatory regions that are targeted by two transcription factors that are required for ASC development. Finally, in the revised manuscript, we identify IFNγ-dependent epigenetic changes in two genes (IL21R and PRDM1 (Blimp1)) that are known to be required for ASC differentiation. These changes in chromatin accessibility occur independently of IL-21 signaling in the IFNγ + IL-2 stimulated cells and are accompanied by increased IL-21R expression, enhanced IL21R-dependent signaling and B cell differentiation. Interestingly, these IFNγ-dependent differentially accessible chromatin regions (DARs) are also present in the IL21R and PRDM1 loci in SLE DN2 cells, suggesting that these DARs may be regulated by IFNγ in these SLE patient B cells.

> I simply don\'t get these figures at all, in addition to be very complex. One curious comment was that the Tbet^hi^ B~DN~ Be1 cells are responding to endogenous TLR ligands. That is pretty curious, and I wonder what evidence there is and what endogenous ligands they think are in action?

As described above, the IPA analysis shown in the original Figure 5A predict that the TLR7 and TLR9 signaling pathways are activated in Be1 B~DN~ cells relative to Be2 B~DN~ cells. This means that known downstream targets of the TLR7/8/9 signaling pathways are, in general, more highly expressed in Be1 B~DN~ cells. The interesting question, as noted by the reviewer, is why the TLR pathway(s) are activated in the Be1 B~DN~ cells when we did not add exogenous TLR ligands to the co-cultures. The most likely answer is that, like other have reported (Sindhava et al., 2017), endogenous TLR ligands are released by dying cells in the cultures. However, while this may explain where the TLR ligands are coming from, it does not explain why TLR signaling pathways are activated in the B cells from the Be1 cultures compared to the Be2 cultures, particularly since the frequency of dying cells is not different in the Be1 and Be2 co-cultures (data not shown). Therefore, we hypothesized that Be1 B~DN~ cells must be more responsive to the endogenous TLR7/8/9 ligands that are present in both cultures. In support of this conclusion, we provide new data in the paper (revised Figure 9A-C and [Author response image 4](#respfig4){ref-type="fig"}) showing that B cells activated (with TLR7/8 ligand + anti-Ig + IL-21 + IL-2) in the presence of IFNγ respond to a 100-fold lower dose of TLR7/8 ligands than B cells stimulated with the same activation cocktail minus IFNγ ([Author response image 4A-B](#respfig4){ref-type="fig"}). In fact, the IFNγ-stimulated B cells stimulated with low dose TLR ligand proliferated vigorously ([Author response image 4A](#respfig4){ref-type="fig"}) and efficiently differentiated into ASCs ([Author response image 4B](#respfig4){ref-type="fig"}) when activated with low dose R848, while B cells in the cultures that did not include IFNγ remained undivided and did not differentiate into ASCs ([Author response image 4A-B](#respfig4){ref-type="fig"}). Furthermore, cross-titration experiments with IFNγ and R848 demonstrated clear synergy between these two signaling pathways and revealed that B cells activated in the presence of IFNγ can respond to normally non-stimulatory concentrations of R848 (0.01 µg) (see [Author response image 4C](#respfig4){ref-type="fig"}). We believe that these data explain why B cells activated under Be1like conditions (IFNγ stimulated) exhibit a TLR activation signature as these cells are exquisitely sensitive to the low levels of endogenous TLR ligands that are likely to be present in our in vitro cultures. More importantly, the data suggest that B cells that are activated in the presence of IFNγ are "primed" to respond to even very low levels of TLR ligands. We believe that this finding explains why the IFNγ experienced T-bet^hi^ DN2 cells from SLE patients exhibit increased responsiveness to TLR ligands (Jenks et al., 2018) and why T-bet expressing B cells contribute to disease pathogenesis in the Lupus-prone animals with a TLR7 gene duplication (Figure 1---figure supplement 1). We make these points in the revised manuscript.

> I also find it very puzzling that the culture returns the result that IFNγ is a potent B cell mitogen or facilitator of B cell proliferation (Figure 8). This is, as far as I am aware, a unique finding.

There is no data that we are aware of in the literature to support the conclusion that IFNγ is a potent B cell mitogen. Instead, our data support the conclusion that IFNγ facilitates B cell proliferation by enhancing the B cell response to TLR7/8 ligands, which are known to induce proliferation. Indeed, IFNγ-mediated enhancement of B cell proliferation is largely lost when TLR ligands are not included in the cultures (see rev. Figure 9A and [Author response image 4A](#respfig4){ref-type="fig"} -- compare proliferation profile of cells stimulated ± IFNγ in the presence of no R848 vs 0.1 µg/ml R848). This point is made more clearly in the revised discussion of the manuscript.

> Last within this group I take issue with the statement that the experiments in Figure 9 test in any way the hypothesis that \"IFNγ-induced Tbet might alter the epigenetic profile of the B cells\". The results do not support the subsequent conclusion that by \"promoting upregulation of Tbet, which modifies chromatin accessibility of the IL21R locus in the IFNγ stimulated B cells\". No. An association is shown but there is definitely no causation.

Yes, association does not equal causation and we modified the text accordingly.

> Figure 10 appears to be based on 1 patient and to show that disease activity (as measured by antibody titres) correlates with the appearance of Tbet^hi^ B~DN~ cells. Again, I am reasonably confident this has been reported, maybe with slightly different criteria, but same message.

The original Figure 10A (now revised Figure 1J) examined the correlation between the frequency of circulating T-bet^hi^ B~DN~ cells (DN2 cells) and the titers of anti-Smith Ab. The number of donors in this analysis is 18 (not 1). Similar data was recently published by Jenks et al. (Jenks et al., 2018) from a separate cohort of SLE patients.

The other panels in the original Figure 10, which include functional and phenotypic analyses, were performed with B cells from n = 2-3 SLE patients. These data are now found in revised Figure 1H-I (n=3 independent patient samples), revised Figure 5E and G (n=3 independent patient samples) and revised Figure 5P-Q (n=2 independent patient samples).

> This figure is intended to tie the study together to show that the Tbet B~DN~ cells in SLE patients have the differentiation potential that has been described for B~DN~ cells derived in the in vitro cultures. They do, to an extent, but is this sufficient proof to say that the processes used in vitro to produce these cells in vitro are the processes that occurred in vivo to make the phenotypically similar cells? I think not.

While it is true that we cannot conclusively prove that the stimuli defined in our culture system fully recapitulate the complex microenvironment and signals that the SLE B cells are exposed to in vivo, we do think that we have identified at least one important and underappreciated signal (IFNγ) which clearly augments ASC formation by increasing the responsiveness of B cells to TLR ligand and IL-2 and preparing the cells to respond to IL-21. Moreover, we show that the T-bet^hi^ B~DN~ pre-ASC population that we can induce in vitro with either Th1 cells + IL-21 + IL-2 or with defined stimuli (IFNγ, TLR7/8 ligand, BCR ligand, IL-2 and IL-21) exhibit molecular, epigenetic, phenotypic and functional properties of preASCs as well as the T-bet^hi^ DN2 population that is expanded in a subset of SLE patients, particularly those patients who present with an elevated systemic IFNγ-driven cytokine signature.

> In part this is due to the what I think is the very poor efficiency of the culture system in which 10\^5 B~DN~ B cells were put in for stimulation but only 400 IgG ASC came out? (Figure 10K).

We removed these data from the revised manuscript. It is true that we only detected \~400 ASCs in the original Figure 10K from an input of sorted 100,000 T-bet^hi^ DN2 cells. However, we do not think that this is due to the poor efficiency of the culture system but rather to the fact that we sorted the pre-ASC DN2 cells and let the cultures go for 6 days. What we know is that DN2-like cells are poised to rapidly differentiate into shortlived ASCs once exposed to IL-21 and do not require multiple rounds of cell division. By contrast, memory B cells can proliferate and then differentiate. So, by day 6, we believe that the response of the DN2 cells is well past the peak and most of the short-lived ASCs have already died. By contrast, the memory B cell cultures can continue to divide and to generate ASCs for many days. This is why in the revised manuscript we now specifically look at a much earlier timepoint (2.5 days of stimulation, see revised Figure 10N). When we examine this timepoint, we can see that the frequency of ASCs in the cultures containing Tbet^hi^ DN2 cells is only 2-3 fold lower than the cultures started with memory B cells and orders of magnitude higher than that seen in cultures started with the T-bet^lo^ naïve B cells. Thus, we argue that in a 2.5 day window T-bet^hi^ DN2 cells differentiate nearly as efficiently as the memory B cells and much better than naïve B cells. Moreover, while the frequency of ASCs in both the memory B cell cultures and the T-bet^hi^ DN2 cultures appears low when compared to publications examining in vitro differentiation of memory B cells, it is important to remember that we looked much earlier than has been done in the prior publications (that are typically enumerated between day 5-7 or even out to day 10). If we extend our cultures started with memory B cells, which continue to divide, out to 4 days, well over half the cells in the cultures are ASCs. Thus, we believe that our culture system can efficiently generate ASCs from naïve B cells, from memory B cells and from DN2 cells. However, ASCs derived from the DN2 cells, which differentiate without only limited additional cell division, need to be measured early while ASCs that are derived from naïve or memory B cell precursors are best measured late, after the cells have been activated to proliferate and then differentiate.

> Overall this is a long, complicated and ultimately hard to follow report that I don\'t think supports the claimed conclusions.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Thank you for your resubmission and the efforts to address the reviewers comments. Reviewers were satisfied on how you have addressed their comments, but at the same time they are concerned about the presentation of the manuscript. As you will see from their comments, there is a sense of a large amount of data but a lack of clarity in the overall message. At this point, we do not require from you new data to be added to the manuscript, but we would like to ask you to make an effort to streamline the text to make it clear and easy to follow, with main novel data in the main figures and the supporting material in supplementary. We are attaching reviewers comments of reviewer 3 so you can address the issues.
>
> Reviewer \#1:
>
> Authors addressed all my concerns. They generated a new figure showing that t-bet+ B cells appear following flu vaccination and they are phenotypically similar to the DN2 B cells found in SLE patients and B~DN~ cells generated in their ex vivo culture system. They should consider adding this figure as supplementary for the paper and shortening the main text. I support its publication in eLife.
>
> Reviewer \#2:
>
> The authors have made a strong and commendable effort to address the concerns I articulated in the first review. This version of the manuscript is a marked improvement, and for the reasons articulated in the first review feel this paper can now be published.
>
> Reviewer \#3:
>
> I note with some regret that virtually nothing I suggested has been acted on other than the very obvious corrections and improved scientific practice. I still find the paper overly long, overly complex, somewhat repetitive of existing information -- including from papers published by this group -- and also somewhat self-serving. By this last term I mean that having made (again) the observation that there are expanded Tbet+, activated B cells in SLE patients, it is now claimed in the discussion that the expansion of these cells in SLE is predicted by their discovery (Discussion section).
>
> The manuscript remains very long (10 figures with 135 panels; 2 supplementary figures and 6 supplementary files; 85 references; 5 pages of discussion etc.), very complex and somewhat impenetrable. I note also that the other referees do not share any/many of my concerns, so I accept that these futile requests for clarity and brevity are probably more about me than anything else.

There was a sense of a large amount of data but a lack of clarity in the overall message. We were therefore asked to make an effort to streamline the text to make it clear and easy to follow, with main novel data in the main figures and the supporting material as supplementary materials.

To that end, we have made the following changes in revision 3.

1\) Reduced the number of main figures from 10 to 8. We moved some data (particularly representative flow cytometry plots and gating strategies) to supplement files. We also removed some of the less critical panels/data all together.

2\) The Results section is now reduced by 22%.

3\) The Discussion section is decreased by 32%.

4\) The references have been reduced from 85 references to 67.

5\) The figure legends have been reduced by 26%.

6\) We moved supporting data to supplemental and now have 13 Supplementary files to support the main 8 figures. Many of these Supplementary files are single panels. We have 5 Supplementary Tables (Excel files with RNA-seq, ATAC-seq, GSEA gene lists, P values for HOMER motif analyses, and Statistic tables).

In total, we have reduced and consolidated the main sections of the paper by 20%. I believe that the manuscript is now easier to digest and flows more logically.
